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Automatic analysis of single sweep evoked potentials: a tool for neural monitoring in neurosurgery
Liberati D. (Milano) Introduction -Head tumor neurosurgery,besides the therapy effect, could involve accidental neuronal damages, because of local heating induced by electrosurgery. The skill of the surgeon can be improved via dynamic evoked potential monitoring. Such a procedure is currently followed at New York University since many years in case of posterior cranial fossa surgery: the use of the conventional averaging procedure over hundreds of sweeps, in order to detect the evoked potential, implies a delay of several seconds between the initial occurring of the damage and its recognition. The methodology here presented has the aim of reducing such a delay, by identifying the dynamic changes of the evoked potential on a single-stimulus response.
Materials and methods -Evoked potentials are recorded with usual protocol at the Istituto Neurologico "C. Besta" and at Istituto "S. Raffaele', in Milano, both during neurosurgery and in simulation sessions: in these ones, the stimulus intensity is attenuated in order to emulate the dynamics of the damage, whose eventuality is emulated by absence of stimulation. After proper pre-filtering, digital conversion is performed on a personal computer for a processing via stochastic parametric identification and optimal filtering. Results-The processing, initialized before surgery with the average, gives the dynamics of each single sweep in a time of about 1 see from the stimulus. Presence or absence of the evoked potential are always correctly detected, as well as modified responses. The precision in quanitify the modification is decreasing when the response is worsening.
Conclusions-Single-sweep evoked potentials analysis performs nearly on line monitoring of the neural pathway related to the selected stimulus, when neurosurgery is undergoing.
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-D. LIBERATI ET AL.: Medicina e Informatica 3(4):13-21, 1986 -D. LIaERATI ETAL.: J. Biomed. Eng. I 1: 285-292, 1989 -D. LIaERATI ET AL. : IEEE Trans. Bim. Eng. (in press) 1991a -D. LIBERATI ET AL.: Med. & Biol. Eng. & Comput. 29:159-166, 1991b 2. ABR monitoring in rhinopharyngeai carcinoma treated by radiotherapy; preliminary results Guglielmetti R., Pisani P., Krengli M., Pia F. (Novara) ABR can be successfully used in monitoring pathological conditions involving brainstem structures. The Authors, by ABR testing, analyse the possible brainstem induced alterations following radiotherapy in patients affected by epipharingeal tumors extended to rhinobasis structures. Case report includes 16 patients, 10 males and 6 females, aged from 37 to 82, all affected by undifferentiated rhinopharingeal carcinoma at the IV stage.
All the subjects were submitted to Co 60 radiotherapy (55-70 GY): brainstem received from 50 to 100% of the complexive dose.
Otoneurological examination before and after radiotherapy was performed by: -pure tone audiometry -timpanometry and acoustic reflex -rotatory tests -saccadic eye movements -smooth pursuit -ABR Our considered ABR parameters were: wave I-V interpeak interval (CCT) and absolute wave V latency. After RT treatment ABR analysis pointed out a wave I-V interpeak interval abnormal in 40% and pathologic in 37%. The most significant variations were in patients irradiated with more than 60 Gy. From a statistical point of view all data were significant (p. 0.01). In our experience, ABR parameters abnormalities let to suppose a straight relationship between these modifications and a radioinduced acute damage.
A peroperative study with evoked potentials of two cases of cavernous angiomas of the brainstem: clinical and elettrophysiological correlations.
Fava E., Campanella R., Bello L., Villani R.M. (Milano) Two cases of cavernous angioma of the brainstem, respectively located in the pons and in the dorsal midbrain are reported. The former patient had a large lesion occupying the greatest part of the pons, with recent bleeding more extended to the fight side. The latter patient had a small angioma of the quadrigeminal plate. Preoperative study with brainstem auditory evoked potentials (BAEP), somatosensory evoked potentials (SEP) and pattern reversal evoked potentials (PR-VEP) showed i) in the first case, a bilateral modification of BAEP and cortical SEP, associated with normal visual evoked responses, suggesting a dysfunction of the cranial brainstem, more relevant on the right side; ii) in the second ease, only a moderate abnormality of visual evoked responses with normal BAEP and SEP. Both patients were submitted to surgery in the sitting position, and operated throught a suboceipital-supracerebellar approach in the first ease and through a suboccipital-transtentorial approach in the second case. Intraoperative monitoring of the brainstem was performed by BAEP and SEP.
In the first case, the cortical SEPs could be recorded only during the first phase of surgery, while they were then abolished, probably due to air entrance within the subarachnoid spaces, as confirmed by postoperative CT scan. BAEPs were available throughout surgery; the most relevant modification was a transient obliteration of wave V during the coagulation and the removal of the angioma, followed by a fast recovery. Only a transient worsening of the oculomotor disturbances was apparent in the postoperative course. Postoperative recording of evoked responses, performed three weeks after surgery, pointed out a unilateral normalization of BAEP, and an improved morphology of the cortical SEP responses.
In the second patient, BAEP and SEP were available throughout surgery. Significant alterations were transiently observed only as a consequence of bradycardia and hypotension. In these cases a derangement of N20/P25 complex of cortical SEP, with reduction of amplitude and increase of duration, was noticed. The BAEP showed at most a small prolongation of I-V conduction time. All these modifications were always and readily reversed by the cardiovascular normalization. However, at the end of the surgery a stable reduction of the amplitude of the cortical SEP over the right emisphere developed. This alteration could be connected with the development of a right temporo-occipital deep haemathoma.
After the surgical removal, SEP and BAEP normalized. These results suggest some considerations about the problmes of both the generators of evoked responses within the brainstem and how to perform a correct monitoring of these patients: 1) the pons and the medulla are fairly monitored by BAEP; 2) the dorsal midbrain probably represents a silent area for both BAEP and SEP; as a matter of fact the intraoperative monitoring can be inade-quate to prevent complications at this level; 3) during brainstem surgery hemispheric injuries due to cardiovascular failure for the sitting position, might develop; cortical SEPs have a high sensivity in order to point out impending supratentorial ischemia. For this reason, they could be considered as a fundamental tool in intraoperative monitoring; unfortunately, 4) the air entrance within the subarachnoid spaces due to sitting position may abolish the cortical SEP.
4. Brain-stem auditory evoked potentials in supratentorial brain tumors Pace A., Pietrangeli A., Bove L., Morace E., Jandolo B. (Roma) A group of 42 adult patients with supratentorial brain tumors were studied with computed tomography (CT and/or NMR) and brain-stem evoked potentials (BAEPs). 12 patients had meningiomas and 30 had malignant tumors (gliomas and metastases). The latencies of wave V and of the interpeak latencies I-III, III-V, and I-V were evaluated both on the lesion side and the opposite side. In meningiomas mean latencies did not show significant differences from normal, while mean latencies in malignant tumors were significantly prolonged, except for the I-III interpeak latency. The utility of BAEPs in monitoring of supratentorial brain tumors after treatment is discussed.
The VEPs in evaluation of pituitary tumors and optic nerve glioma
Pietrangeli A., Bove L., Innocenti P., Occhipinti E., Carapella C.M., Caroli F. and Jandolo B. (Roma) The clinical value of the VEPs in neuro-oncology is based on their sensitivity in detecting an early involvement of pre-chiasmal visual pathways and of chiasmal compression from pituitary tumors. Moreover, the half-field stimulation and the multi-channel recording can provide further diagnostic data in addition to CT scan or [MRI] . We studied 12 patients with sellar and suprasellar compressive lesions (5 pituitary adenomas, 5 craniopharyngiomas, 1 suprasellar dermoid, 1 ectopic pinealoma). 2 patients were tested before surgery, 3 before and after surgery and 7 only after treatment. VEPs were recorded also in one patient operated for optic nerve glioma. This test was performed every 6 months to control the extention of the lesion. The utility of this test is discussed.
The prognostic value of inflammatory infiltrates in gliomas is still debated. However, the finding of a paucity of lymphocytes infiltrating the gliomas is well established. So far, few studies investigated the macrophages infiltration in brain tumors and these studies were performed in frozen sections with poor morphologic resolution.
In the present study we analysed the inflammatory infiltrates in different grade gliomas. Particular attention we adressed to the macrophages infiltration and we correlated the grade of their infiltration with the survival of patients. Biopsy samples from 40 cases of different grade gliomas were routinely processed (formalinfixed and paraffin embedded). Diagnosis were performed in H&E stained sections. Monoclonal antibodies (mab) anti-T and B lymphocytes and anti-macrophages were applied to the fixed sections. An immunoperoxidase method with avidin-biotin amplification was used to visualize the reactions.
In our study, macrophages were the principal inflammatory cell infiltrating gliomas and their constant presence in high numbers also in nonnecrotic areas suggests an active role in host defence against tumors. However, in few cases that presented different grade of anaplasia, no inflammatory cells were detected. In other gliomas numerous macrophages were intermixed to ariaplastic astrocytes and accounted for the 40% of cells.
The correlation between macrophages infiltration and survival of patients is ongoing.
Planimetric evaluation of well differentiated astrocytomas on stereotactic biopsies
Fadda G., Scerrati M., Minimo C., Roselli R., Zannoni G.F, lacoangeli M., leraci A., Rabitti C. (Roma)
The grading of the astrocytomas is one of the most debated topics in the neuro-oncological field: although a quite large number of classifications has been so far proposed concerning the graduation of these neoplasms, neither of such methods has fully agreed with both morphological and prognostic criteria; to bypass this problem many quantitative techniques have been so far developped: among them the stereology has resulted one of the most interesting. Moreover the problem of the histopathological grading has urgently revealed in the characterization of the glial tumors on the stereotactic biopsies, where the grading may result in a quite different operative management. Our study has been carried out by evaluating quantitatively the nuclear area, maximum diameter, form-factor and density and the hyperplastic vessel wall ratio on the stereotactic specimens obtained either from the peritumoral area in 28 cases chosen as controls or in the turnout mass of 35 differentiated astrocytomas (t 7 grade 2 and 18 grade 3 according to the W. H.O. classification, 1979) . All the measurements have been performed on a Leitz ASM 68 K semiautomatic image analyzer connected by means of a w/b camera Varioscan VI6 a microscope Leitz Dialux 20 EB and to a graphic tablet with optical pencil indepedently by two pathologists for each parameter and for each case; then the quantitative data have been statistically analysed by means of a simple linear regression and by comparing the Pearson's r correlation coefficient for the interobserver variation and with a one-way analysis of variance for the comparison between the means of the groups (G2 and G3 astrocytomas and control cases).
The results confirm the reliability of the planimetry in the quantitative expression of the morphological features and may suggest the hypothesis that the nuclear density and the hyperplastic ves-sel wall ratio represent the most significant characters in the assessment of the histopathologic grading in the atrocytomas on stereotactic biopsies. 160-169, 1984 -SCnIFFER D. E COLL.: Cancer61: 1386 -1393 , 1988 . Polio B., Cajola L., Franzini A., Bugiani 0., Broggi G. (Milano) Aim of our study was to compare the proliferative potential and the histological findings of gliomas of the thalamus and the basal ganglia. Cell kinetic data were obtained measuring the number of nuclei with incorporation of 3H-timidine (S phase of cell cycle) and that of nuclei immunostained by the monoclonal antibody anticyclin, a 36kD nuclear protein, auxiliary of DNApolymerase fi (late GI phase and S phase).
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Cell kinetic of deep glial tumors
The study was carried out on 15 stereotaetic biopsies of gliomas from thalamus and/or basal ganglia. The results demonstrate that the presence of histological features of active growth better correlate with the cell kinetic values obtained with anti-cyclin immunohistoche mistry than with those obtained with 3H-timidine. This difference might depend on the sampling of the tissue specimens: anti-cyclin immunohistochemistry is applied to a histological section of the whole biopsy, whereas 3H-timidine analysis is performed only on a portion of it. On the basis of these results, anti-cyclin antibody may recommended as validation of the histological diagnosis of stereotactic biopsies in deep glial tumors.
Proliferating cell nuclear antigen (PCNA)
immunoreactivity as a potential prognostic index in neuroeetodermal brain tumors. Mottolese M., Carapella C.M., Salzano M., Raus L., Calvosa F., Benevolo M., Cione A., Bigotti A., Riccio A., Natali P.G. (Roma) Monoclonal antibody PC10 recognizes a 36 Kd nuclear protein associated with cell proliferation in paraffin embedded tumor specimens. In the present study we have evaluated PCNA immunoreaetivity in a series of 50 neuroeetodermal brain tumors of different histotype, with the aim of assessing whether PCNA expression could be a reliable index of cell proliferation and correlate with other histological and immunohistochemi-cal (Ki67, GFAP) parameters as well as with clinical outcome. Present results indicate that PCNA immunoreactivity may represent a potential prognostic index, particularly for its capacity of identifying focal anaplastic areas in low grade astrocytomas. For this reason PCNA expression could represent another relevant parameter to be studied for accurate biopathological diagnosis of neuroeetodermal brain tumors.
Proliferating cell nuclear antigen expression and DNA content in malignant neuroepithelial tumors: correlation with clinical behaviour.
Gaetani P., Danova M., Bosi F., Knerich R., Giordano M., Lombardi D., Rodriguez y Baena R., Paoletti P. (Pavia) The spectrum of clinical behaviour of malignant neuropithelial tumors shows a wide variety, making the individual prognosis difficult to be predicted. Despite acceptable accuracy for tumor diagnosis, the prognostic value of histopathological data is limited. Tumor grading is predictive but, there is the need of additional prognostic markers intrinsic to individual cases. In this sense, it is possible that a better understanding of proliferative characteristics could allow a better selection of patients suitable for adjuvant treatments, and a better utilization of currently available therapies. Tumor growth is, in fact, a reflection of abnormal cell proliferation and/or differentiation, so that markers of cell proliferation are expected to correlate with tumor gowth rate and be predictive of tumor sensivity to cytostatic agents. Increasing number of nuclear antigens are being involved in cellular events related to proliferative patterns and malignant transformation. Thus, the quantitation of relevant nuclear antigens could provide useful informations, particularly when coupled with the simultaneous quantitation of nuclear DNA. One of these proteins, the DNA-polymerase delta auxiliary factor, called proliferating cell nuclear antigen (PCNA), has been recently characterized and studied in details. In the present study we have performed an analysis with multi-parametric flow cytometry of the DNA content and PCNA expression in surgical samples obtained from 12 patients operated on for malignant neuroepithelial tumors. We have correlated these findings with clinical course, in order to preliminary assess the prognostic value of this parameter. All patients showed diploid DNA content. The median value of S-phase cell percentage (as evaluated by DNA flow cytometry) was 15.5% (range 7.2-18), while the median value of PCNA expressione was 35.9% (range 30-46.5). In all samples, the pattern of PCNA expression was prominent in the late GI phase and through all the S-phase, while it decreased in G2. We found a trend towards a poorer survival for patients with higher value of proliferative activity (i.e. S-phase > 10% and PCNA expression > 300/0). The possibility to correlate DNA content, nuclear antigen expression with a prognostic value is intriguing. In addition, the multiparametric technique shown in the present work, allowed a quantitative assessment of the antigen through the cell cycle rather than a qualitative analysis available with current immunofluorescent techniques. The analysis of correlation existing between PCNA expression, cell cycle characteristics and clinical outcome (with a longer follow-up in a larger series of patients and supported by a multivariate analysis), should help to elucidate the potential value of this proliferative marker.
This study was partially supported by a grant of a National Research Council (CNR), P.F. "Oncologia" n. 88.00841.44.
Expression of growth factors in human brain tumors. Preliminary results.
Licastro G.. Buttarelli F.R., Lunardi P., Nicotina P.A., Palladini G., Fortuna A. (Roma, Messina) The presence of proteic products of selected oncogens in human brain tumors was analyzed in this study. Three such proteic products were particularly focused upon: those of Epidermal Growth Factor Receptor (EGF-R), of Oncoprotein c-erbB-2, and of Proliferating Cell Nuclear Antigen (PCNA). The amplification of such oncogenes, typical of tumoral tissues has been demonstrated in many types of human tumors, both as genes and as proteins. With respect to EGF-R the amplification was observed also in brain lesions: Libermann et al. (1984) have demonstrated, by means ofimmunoprecipitation-extracts and subsequent autophosphorylation high levels of EGF-R in all of non-neuronal origin brain tumors; Strommer et al. (1990) , by means of immunocytochemistry and molecular hybridization revaled an overexpression of EGF-R in over half of malignant gliomas examined. Lastly, the presence of high levels of c-erbB-2 and PCNA was evidenced in some breast adenocarcinomas and lymphomas respectively. By means of monoclonal antibodies anti-EGF-R, anti-c-erbB-2 and anti-PCNA we have studied the distribution of respective growth factors in I0 human brain tumors variously distributed among astrocytomas, oligodendrogliomas, glioblastomas and meningiomas; control speci-mens, from the brain of patients who died from diseases not related to the CNS, were generally prelevated 24 hr postmortem (after about 24 hr at
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The results thus achieved are very promising and confirm that the presence of growth factors is, generally, an expression of malignancy in human cerebral tumors as well. The correlation of immunocytochemistry data with patient follow-up will certainly useful as well.
Oncogene expression in human gliomas
Berger M., Laind J.M., Verna J.F., Brunet J.F., Nissou M.F., Munari C. and Benabid A.L. (Grenoble Cedex) Brain tumors represent about 8% of the human malignancies and 60% of them are gliomas. Their bad prognosis and therapeutic inefficacy benefited from biological studies leading to the concept of oncogenes. In a previous study we investigated the patterns of involvement of ten ontogenes in a series of 38 human brain tumors including 20 gliomas (4 grade I and II, 7 grade III, 9 grade IV), 12 meningiomas and 4 metastasis. Epidermal growth factor receptor (EGF-R) was the most (40%) frequently expressed proto-oncogene in high grade gliomas. In these cases hyperexpression, amplification and protein phosphorylation were correlated. An hyperphosphorylation of the EGF-R was detected in half of these high grade gliomas in absence of EGF stimulation. Results of bidimensionnal electrophoresis added to the polymoprhism of EGF-R activation. We never detected EGF-R in low grade astrocytomas.
Autocrine regulations are fundamental in growth factor receptor activation. Because of direct contact between tumor cells and cystic fluids we searched for an "EGF-like" activity in this tumoral area. Paradoxically all of the 20 CFs (associated with gliomas) inhibited EGF-R phosphorylation. Biochemical study suggested an anti-tyrosine kinase activity. These results suggest that the role of EGF-R is non etiological in glial oncogenesis. It may partecipate to progression ofneoplasia. The finding of an anti-tyrosine kinase activity in CF supports the presence of proto-oncogene modulating activity in the tumoral tissue itself. Oncogenes and anti-oncogenes study, in absence of etiological key to gliomas, may permit some prognosis and therapeutical applications. However their current analysis calls for biotechnological progress, especially for application to stereotaxic surgery. We show the application and feasi-bility of automated electrophoresis to molecular assessment of oncogene activation in stereotaxic biopsy. Extension of this work is being performed towards diseases other than cancer. Biochemical changes in epileptic focuses could also involve oncogenes such as the los protein product as demonstrated in animal experimental studies. Preliminary results on human specimens from surgical corticectomies (6 patients with temporal epilepsy: 2 cryptogenic and 4 associated with low grade astrocytomas) are reported.
Analysis of the oncogenes c-met and c-N-ras in glioblastoma cell lines
Faggioli L., Tognon M., Colombatti M., Tridente G., Suzuki H., and Gerosa M. (Verona, Ferrara) Polysomy of chromosome 7 is a frequent cytogenetic alteration in glioblastoma multiforme. There is probably no relation with the amplification ofthe Epidermal Growth Factor gene (7 p 12p 14), observed in 30-40% of these tumors. Therefore, the molecular basis for polysomy of chromosome 7 might be related to another gene mapping on the same chromosome. We have examined the gene copy number and the level of expression of the c-met oncogene, located on chrosomome 7 (7q31-q32), encoding a transmembrane protein with structural features of a tyrosine kinase receptor. Southern blot hybridizations on a panel of human glioblastoma cell lines showed amplification of the c-met oneogene. This result correlated with the increased copy number of chromosome 7. Furthermore,.the cell lines analyzed expressed appropriate amount of the c-met mRNA. We are presently performing the same analysis on fresh surgical biopsies. The presence of point mutations activating the c-N-ras oncogene has also been investigated. Using the Polymerase Chain Reaction, the first and the second exon of c-N-ras gene were amplified and directly sequenced. No point mutation was observed.
lmmunotoxins in brain tumor immunotherapy
Candiani C., Franceschi A., Chignola R., Pasti M., Benoni G., Anselmi 0., Stevanoni G., Gerosa M., Tridente G., and Colombatti M. (Verona) Surgery, chemotherapy and radiotherapy have been showing limited success against higly malignant brain tumors. Newer pharmacological agents are being investigated with the aim of increasing therapeutic effectiveness as well as improving the grim prognosis of these patients. Particular emphasis has recently been given to cell selective mAb/ligand-toxin conjugates (Immu-notoxins) that kill tumor cells by enzymatic mechanisms. Anti-Transferrin Receptor (TFNR) lmmunotoxins have been synthetized using mAb OKT9, OX26 or human Tfn linked to the A subunit of the potent cytotoxin ricin (RTA). Anti TfnR RTA immunotoxins kill human and rat glioblastoma cells in vitro (monolayer and spheroid cell culture) at nanomolar concentrations, in the presence of the ionophore monensin (Mo). Methods have been devised to cross-link Mo to carrier proteins (i.e. HSA), to reduce its in vivo clearance and to allow RTA Immunotoxin potentiation in vivo. An animal model (rat) is being developed to evaluate toxicity and pharmacokinetics of RTA-Immunotoxins and of HSA-Mo conjugates following intrathecal inoculations into the CSF compartment. Preliminary, experimental results, seem encouraging. 
Study on the association of BK virus with human brain tumors
Faggioli L., Negrini M, Corallini A., Barbanti-Brodano G., Suzuki H., Tognon M., and Gerosa M. (Verona, Ferrara) BK virus is a neurotropic papovavirus ubiquitous in human populations. Its oncogenic properties include the ability to transform rodent and human cells in vitro, and to induce cerebral and pancreatic islets tumors, osteosarcomas and fibrosarcomas when inoculated in hamsters. BKV DNA was detected by Southern blot hybridization in human brain and pancreatic islets tumors. Using the Polymerase Chain Reaction we analyzed the DNA from 16 cerebral tumors and from normal brain, in order to verify the presence of DNA sequences homologous to BKV. We amplified the regulatory region of BKV spanning between two regions conserved in all the isolated variants. In the wild type virus, the sequence between these two regions is 318 bp, while in the other strains is of variable lenght. This heterogeneity enables us to understand which variant is present in the analyzed DNA. Aliquots of the amplified DNA were examined by gel electrophoresis. A 260 bp fragment --potentially belonging to the Dunlop strain --was visualized by this technique. Its specificity was proved by molecular hybridization of the amplified DNA with an oligonucleotide internal to the amplified fragment. The cellular or the viral origin of these sequences is under investigation.
Biologic Features of Embryonic-Appearing Neuroepitheliai Tumors. Rorke L.B. (Philadelphia)
Tumors composed primarily of embryonic-appearing neuroepithelial cells and occuring most commonly in childhood have intrigued neuropathologists for many years. Divergent theories regarding their natur and cell of origin have been proposed from time to time, the most widely accepted being that advanced by Bailey and Cushing in 1925, and elaborated more recently by Rubinstein. Alternative views of del Rio Hortega and Polak have been less popular whereas studies of Gullotta suggesting that tumors of this histological appearance are primarily mesenchymal rather than neuroepithelial have gained little support. Re-evaluation of these diverse views and investigation of the nature of the cells comprising these neoplasms led Rorke and colleagues to suggest that adherence to theories regarding "cell of origin" are not only unprovable but irrelevant. Since neoplastic cells do not necessarily follow developmental programs of their normal counterparts identification of which precise cell type has undergone transformation is less important than determination of their biologic features. A thorough elucidation of the cellular nature of this group of tumors should facilitate resolution of the current nosologic controversy.
Biological and ultrastructural characterization of human meningiomas: preliminary report
Oppido P. A., Scarpa S., Broglia L., Salvati M., Delfini R. (Roma) The biological study in vitro and ultrastructural analysis can give several informations about the characterization and classification of brain tumors. At moment their usefulness in diagnosis and prognosis has not been yet established, because of economic and technical problems. Our preliminary study is intended to solve the technical problems and evaluate those biological and ultrastructural findings useful in characterization and prognosis of human meningiomas. We suggest that these data, in addition to light microscopy, may be determinant not only for a more precise diagnosis of mixed types, but even to observe atypical biological behaviours, as prognostic features. We have until now analyzed 15 tumoral specimens: 8 meningiomas, 3 gliomas, 2 lymphoma~, 2 neurinomas. Every sample has been examined by light and trasmission electron microscopy, while only 12 in vitro tissue cultures resulted successful. Cell proliferation has been quantified by 3Htimidine incorporation for each tissue culture and the results plotted on a histogram. Meningiomas biological and morphological features have been compared to those of other tumors as control group. Biological and ultrastructural data have been correlated with WHO classification and clinical-surgical findings. The follow-up and number of patients examined is low for final results, but our preliminary experience explores the biological and ultrastruetural characteristics that may be useful in diagnosis and prognosis of human meningiomas. Capelli A., Piantelli M., Rinelli A., Macri E., Maggiano N., Larocca L.M., Scerrati M., Roselli R., lacoangeli M., Ranalletti F.O. (Roma) Eleven meningiomas were investigated for the presence of estrogen receptors. We found that these tumors specifically bound estradiol. This binding almost exclusively resulted from the presence, in all the cases tested, of high number of type II estrogen binding sites (type II EBS) (from 450 to 2320 fmol/mg of cytosoi proteins).
Type II estrogen binding sites and flavonoids in meningiomas
Estrogen receptors were absent (8 cases) or present at very low concentrations ( < 10 fmoi/mg of proteins). Type II EBS display lower affinity but higher capacity for the ligand than ER. Owing to the relatively low binding affinity (Kd 12-20 nM) of type II EBS for estrogens, it is hard to imagine that these sites could be occupied by estrogens in vivo. A solution of this paradox has partially been realized by the observation that type I I EBS in rat uterus are occupied by a ligand with growth inhibitory activity. Thus the physiological function of type II EBS might not be to bind estrogen but rather to bind the type II ligand. Although this ligand has bot been structurally identified, some evidence suggests that it may be a plant flavonoid-like molecule, probably of dietary origin. We have then tested different flavonoids for their ability to compete with estradiol for type II EBS in meningiomas. These specificity experiments demonstrated that quercetin (pentahydroxyflavone) is able to inhibit the binding of tritiated estradiol to type II EBS with a potency similar to that of diethylstilbestrol. In order to evaluate the Q sensitivity of proliferating tumor cells we used bromodeoxyuridine (BdU) uptake that was then identified immunocytochemically. In vitro incubation of small fragments of meningiomas with l0 uM Q produced tested 81% and 90% reductions in the number of BdU labelled cells in the 2 cases tested. Furthermore, the rhamnosyl-gluco-side ofQ (rutin) and hespertin-7-rutinoside (hesperidin) that do not compete with estradiol for type II binding, do not inhibit the proliferation of meningioma cells. Since type II EBS are related with the control of cell growth, it can be hypothesized that these binding sites may represent a biochemical parameter with possible prognostic significance. In addition, the growth inhibitory properties of Q, together with the presence of type II EBS in meningiomas suggest that this substance could be of some therapeutic potential.
TGF-I31 induces DNA synthesis in meningioma cultures
Di Sapio A., Mauro A., Schiffer D. (Torino) Transforming growth factor I~ polypeptides can be considered multipotential growth regulators for different cell types. TGF-13 molecules can induce a proliferative response on cells of mesenchymal origin. Our previous studies indicated that meningioma biopsies express high levels of TGF-131 mRNA. In this study we have analyzed the mitogenic response to TGF-~I of three meningioma cell primary cultures. In all cases TGF-I~I; produced a clear dose-dependent increase in [3 H]thymidine incorporation. Taking into account that a TGF-131 like activity has been previously demonstrated in meningiomas as well as TGF-131 gene expression, our results suggest that TGF-[~I may be a growth promoting factor for human meningiomas. A cooperation with Platelet Derived Growth Factor may be hypothesized in the interpretation of the growth stimulation activity of TGF-I~I on menin-
Coexpression of PDGF [3-receptors and of a PDGF-Iike growth factor in meningioma cultures.
Mauro A., Di Sapio A., Bulfone A., Schiffer D. (Torino) In vivo studies indicated a coexpression of Platelet-derived growth factor (PDGF) and of PDGF 13-receptor genes in human meningioma biopsies. These findings suggest the presence of an autocrine growth loop in these tumors. In three primary meningioma cultures we have studied the distribution of PDGF co-and 13-receptors, the mitogenic response to PDGF isoforms, and the production of PDGF-Iike growth factors. MAb against PDGF 13-receptor constantly immunodecorates meningioma cells, while PDGF co-receptor MAb gave negative results. The AB and BB dimers of PDGF produced an increase in [3H]thymidine incorporation. Conditioned me-dium from meningioma cultures produced an increase of [3H]thymidine incorporation in cultures of Swiss 3T3 fibroblasts and this mitogenic effect was reduced by neutralizing PDGF antibodies. Our results demonstrate that meningioma cells express high levels of functional PDGF [3-receptors and are sensitive to the mitogenic stimulation produced by PDGF AB and BB isoforms. Moreover, meningioma cells in culture secrete a PDGF-Iike growth factor. The coexpression of PDGF receptors and ofa PDGF-Iike growth factor indicates the existence of an autocrine growth loop in meningioma cultures. In line with this hypothesis PDGF antibodies can reduce 3H-Thymidine incorporation in meningioma cell cultures.
lntracranial meningiomas: correlation between polyamines and histotype.
The polyamines: Putrescine (Pu), Spermidine (Spd), Spermine (Sp), are small aliphatic molecules related with the DNA. Their concentrations are elevated in normal growing tissues and in neoplastic tissues. We measured the polyamines using high pressure liquid cromatography in bioptic samples obtained from meningiomas during the operation. We obtained different patterns of polyamines with differences between the single polyamines in different histological subtypes. An active transformation of Putriscine into Spermidine, indicating a faster metabolic rate was found in the more aggressive histotypes. These data prospect a classification of meningiomas based on biological and functional parameters. We are presently verifying a possible correlation between the Spd/Pu ratio and the recurrence rate. We are evaluating meningioma patients with follow-up longer than six years. Aim of the followup study is to verify if the Spd/Pu ratio offers a reliable prognostic clue.
Planimetric analysis of recurrent pituitary adenomas
Fadda G, Anile C., Zannoni G.F., Vari R., leraci A,, Macri E., Maira G. (Roma) Pituitary adenomas are an interesting topic in the pathological field since traditional morphology fails to find a relationship between the biological behaviour, which sometimes may lead to recurrency, and the cytoarchitectural pictures which show little differences between case and case. During the last years several quantitative methods have been developed to point out to such problem: among them the planimetry, which deals with the objective evaluation of the histological structures, has yielded some interesting results even in the neuropathological field. For this preliminary study nuclear area, form factor and density have been measured on the histological specimens of 8 patients who underwent to surgery for the removal of a pituitary adenoma which recurred at least one year after; such measurements have been matched with the ones of a group of 14 cases of adenoma with no recurrence homogenous with them. The measurements have been carried out separately by two pathologists on a Leitz ASM 68 K semiautomatic computerized image analyzer connected either with a graphic tablet with optical pencil or to a Leitz Dialux 20 EB microscope: 3 randomized fields for each case and for each observer at a magnification of about 500x were chosen. First analysis ofthe results shows no significant differences between the values of the parameters in the two groups (first and second surgical specimen) and the control cases, though some differences might be discussed regarding nuclear form factor and density. 
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Growth factors and pituitary tumours
Scanarini M., Boscaro M., Giometto B., Clayton R.N. (Padova, Middlesex) Pituitary tumors may result from either hypothalamic or pituitary defects. Were are currently pursuing the pathogenesis of both functional and nonfunctional pituitary adenomas by comparing tumor DNA with that obtained from lymphocytes of the patient. We have found that allelic deletions of chromosome 11 are involved in the monoclonal development of 60% of non-MEN 1 somatothropinomas, and that these mutations are similar to those occuring in MEN 1 tumors. Although the initiation of cellular transformation may in fact be an intrinsic cellular mutation, subsequent promotion of pituitary tumor growth may require the action of hypothalamic hormones, neuropeptides or growth factors. Expression of several growth factors has been demonstrated in the pituitary gland. We have investigated the cytokines immunoreactivity (IL-I, IL-6) in 25 cases of pituitary adenomas. Proliferating cells, recognized by the MAb-Ki-67, accounted fo 0,5-3% of tumor cells, while macrophages were regulalry detected as folliculo-stellate cells in all cases. No IL-l immunoreactivity was detected in our specimens, while I1.,-6 antibody stained the endothelium in all cases and dusters of cells in few. Giometto B., Bozza F., Alessio L., Tavolato B., Seanarini M. (Padova) Pituitary adenomas are usually regarded as benign, but a few prove to be malignant in behaviour. Histopathological examination has not always been useful in evaluating the biological characteristics of these tumors. The immunohistochemieal demonstration of a proliferating-associated nuclear antigen by the monoelonal antibody Ki-67 allows an easy determination of the cellular growth fraction that is in general agreement with the biological behaviour of tumors. Moreover, the analysis of the Ki-67 expression could allow the evaluation of bromocriptine treatment for prolactin-secreting adenomas and of somatostatine treatment for growth-hormone secreting adenomas. Aim of this study was to analyse the growth fraction of pituitary adenomas with particular attention to the role of pharmacological treatment. The Ki-67 expression in pituitary adenomas was investigated using an immunoperoxidase method with avidin-biotin amplification. The monoclonal antibody (mab) anti-Ki67 (DA-KO) was applied to frozen section of 40 cases of adenomas with different functional aspects (nonsecreting adenomas, prolactin-secreting aden& mas and growth-hormone secreting adenomas). We found a low expression of Ki-67 that ranged from 0.1% to 2% of positive cells. Only in two cases more than 3% of cells were recognized by the mab: one of these cases was a non-secreting adenoma that had a clinically malignant behaviour, while the other was a growth-hormone secreting adenoma that did not responde to the pharmacological treatment. The mean value of growth fraction was lower for the cases treated, in both prolactin-secreting and growth-hormone secreting adenomas.
10-67 expression in pituitary adenomas
Neuroblastoma cell differentiation induced by the combination of 7-Interferon and Tumor Necrosis Factor
Cornaglia-Ferraris P., Lanciotti M., Montaldo P., Ponzoni M. (Genova) Neuroblastoma (NB) is the most common extracranial malignant solid tumour of childhood. Al-though high dose chemotherapy and total body irradiation followed by bone marrow transplantation have extended the long-term survival of patients with metastatic disease, the prognosis remains very poor. Thus, the role of drugs capable to induce NB cell differentiation is presently strongly emphasized. NB arises from the sympathetic nervous system, being the primary tumor more often located in the adrenal medulla. Despite the fact that NB cells are presumably derived from a common transformed progenitor, they usually express multiple phenotypes, including neuronal, neurilemmal (Schwann), epithelioid, and melanocytic. All phenotype may interconvert in vitro either spontaneously or depending on tissue-culture condition. In addition, an in vivo phenotype interconversion has been noticed in tumor masses surgically removed after antiblastic treatment. The aim of a differentiation therapy should then focus on overcoming such a heterogeneity giving raise to a fully mature, proliferation-arrested non-tumorigenic cell, A variety of biological agents and drugs have been reported to induce differentiation of NB cells in vitro. Among these are Retinoic acid, Nerve Growth Factor (NGF), cyclic-AMP, Cytosine-Arabinoside (Ara-C), and phorbol esters. However, totally and/or partially resistant NB cell lines have been described with underlines the need to either search for new agents capable of overcoming cell resistance, or/and to combine it in appropriate experimental models. We recently demonstrated that y-Interferon (2/-IFN), is able to promote concentration-dependent growth inhibition of NB cells, together with striking morphological changes, y-IFN actually modulates membrane antigens and cytoskeletal proteins, inducing a pattern similar to that observed in mature neuronal cells. Moreover, it has also been shown that Tumor Necrosis Factor (TNF) has antitumor, antiproliferative and differentiating activities on various tumour cells, including NB. In addition, TNF is capable to upregulate y-IFN binding in a human carcinoma cell-line, possibly due to the up-regulation of y-IFN-receptor (7:IFNr) expression.
Here we demonstrate that a combination of 7-IFN plus TNF causes extensive and generalized differentiation of NB cells toward a neuronal phenotype. Both y-IFN and TNF, given alone, moderately reduced cell growth and induced partial morphological maturation. Their combination further reduced cell proliferation. The combined treatment gave a synergistic rather than addditive cytostatic effect, documented also by a dramatically enhanced differentiation towards a neuronal morphology. Membrane immunofluorescence showed a homologous and heterologous up-regulation of y-IFN-receptor, as well as, a marked induction of" HLA Class I antigens, and to a lesser extend, of Class II antigens on NB cells induced to differentiate. Treatment of NB cell lines with y-IFN/TNF results in the induction of a differentiated phenotype, as indicated by the increased expression of the 160 and 200 Kd neurofilament proteins, and that of microtubule associated proteins. Evaluation of biochemical markers, of neuronal differentiation, i.e. acetylcholinesterase, catecholamines and related neurotransmitters, confirmed the ability of the combined treatment to induce neuroblast maturation. These results suggest that the combination of 7-IFN and TNF should be considered for experimental clinical trials in neuroblastoma.
Myxochondrosarcoma (chondroid chordoma or chordoid sarcoma). A chordoma mimicking tumor. An immunohistochemical and ultrastructural study in one ease
The chondroid chordoma is nowadays regarded as a mild form of myxochondrosarcoma. In the skull the chondrosarcoma is located in the base whose enchondral ossification takes place in its cartilagineous model. It may also arise from a preceding enchondroma as for instance in the Ollier's syndrome. For the histological aspects and this location the tumor may simulate a chordoma, even the histogenesis of the last is quite different. The Authors present a case conerning a 59 yrs old man who in 1980 complained of exophthalmus with sight lessening in the right eye and paraesthesia in the field of the 5th cranial nerve. A T.C. investigation revealed a tumor in the skull base wich was surgically removed and histologically identified as chordoma. One year later the patient again accused sight and hearing lessening and loss of strenght of both legs. A T.C. examination showed again a tumor compressing the brain stem. The histologic study of the surgicaly removed tumor together with immunohistochemical and ultrastructural investigation led to establish the diagnosis of chondroid chordoma, better named myxochondrosarcoma or chordoid sarcoma.
The diagnosis of cerebral gliomas using the 3 step 99mTc-Biotina immunoscintigraphy
Truci G., Paganelli G., Magnani P. Zenorini A., Zito F., Sudati F.. Maecke H., Reni M., Casadei V., Righi C., Scotti G., Volterrani F., Canal N. Fazio F. (Milano, Basilea) 1.131 labelled MoAbs directed against tenascin, an extracellular matrix antigen, can be used in the imaging of gliomas. We have developed a 3-step immunoscintigraphy method in order to improve the target to non target ratio. The anti-tenascin Mo-Ab BC2 was biotinylated and 0,5 mg were administrated i.v. in 12 patients, 4 with primary gliomas, 7 with recurrent gliomas and I with cerebral haematoma, all histologically documented prior or after scanning. After 3 days, 5 mg of cold avidin were injected i.v. followed, 2 days later, by i.v. injection of 0.2 mg of PAO-biotin labelled with . No evidence of toxicity was observed. Blood clearance of Tc-99m-PAObiotina was multi-exponential, with a fast component (T1/2=2 min) and a slow component (TI/2= 110 min). Tc-99m-PAO-biotina was primarily excreted through the biliary system. Three hours after the injection 43% of the dose was in the liver and 15% in the urine. Brain SPET was performed 60-120 min after the administration of Tc-99m-PAO-biotin using a brain dedicated SPET system (ASPECT).Tumors were detected in 9 of the 11 patients with gliomas, no uptake was observed in the patient with haematoma (CT and M R suspected malignancy). These data suggest that Tc-99m-PAO-biotin 3-step immunoscintigraphy may be used for the diagnosis and follow-up of patients with glioma.
Magnetic Resonance Spectroscopy in tumor cells and tissues
Podo F. (Roma)
In vivo localized Magnetic Resonance Spectroscopy (MRS) allows non-invasive monitoring of metabolic concentrations in animal and human tissues, leading to new perspectives in oncology, for a better biochemical understanding of neoplastic growth and early detection of tumor cell response to in vivo therapy. 31p MR spectra of tumor do not exhibit specific resonances typical of the neoplastic condition. However, in comparison with healthy tissues, significant alterations are usually exhibited by tumors in the relative concentration levels of metabolites involved in bioenergetic pathways (NTP, PCr, Pi) and/or in the biochemical network which regulates phospholipid synthesis and tumover. Water-suppressed tH MR spectra may also display significant alterations with respect to normal tissues, such as reduction of total creatine, increased lactate, increased "choline peak", reduction of N-acetyl aspartate (NAA) levels. Significance and progress of MRS applications in clinical oncology are today limited by difficulties in a) assessing localization, size and content of the selected volume, for absolute metabolite quantification; b) assessing spectral contamination from surrounding tissues; c) clear understanding of biochemical mechanisms underlying the metabolic response of tumor cells to therapy. The Concerted Research Project "Tissue Characterization by MRS and MRI'" (EC Programme on Medical and Health Research, COMAC-BME) faces problems a) and b) at a multi-center level. A summary will be presented of experimental protocols developed by the Project for quantitative MRS analyses and quality control of equipment and procedures. Experimental animal tumors selected for their acceptable levels of tissue heterogeneity and good reproducibility of biological characteristics during growth or regression provide useful tools for both in vivo and in vitro MRS studies. 3~p and *H MRS studies are carried out in our laboratories on a) murine tumors implanted in syngeneic mice and treated with different types of cytokines; b) human melanoma tumours in "nude" mice; c) rat glioma tumours implanted in Wister rats.
Tumors in and around third ventricle: indications and results of the surgical treatment
Tomei G., Grimoldi N., Miserocchi G,,Lucarini C., Beilo L., Gaini S.M., Villani R. (Milano) The experience of 115 patients with tumors of the third ventricle region, admitted at the Neurosurgical Dpt. of the University of Milan, is reported. 20 patients were children, 57 were males and 58 were females. Symptoms at admission were: 35% intracranial hypertension, 25.5% focal neurological deficits, 14% visual disturbances, 10% diencephalic syndrome and mental disorders. According to neuroradiological (CT and NMR) location, tumors were classified as follows: 1) tumors inside the 3d ventricle (32 cases), 2) tumors of the anterior part (20 cases), 3) tumors of the posterior part, with the exception of the tumors of the pineal gland (9 cases) 4) tumors arising from the lateral walls (33 cases), 5) tumors arising from the brainstem (2 cases) 6) tumors arising from the corpus callosum (19 cases). 54 patients were submitted to direct surgical approach: 22 tumors inside the 3d ventricle (40.7%), 14 tumors of the anterior part (26%), 5 tumors of the posterior part (9.2%), 11 arising from the lateral walls (20.3%), and 5 from the corpus callosum (9.2%). Surgical approaches were: transventricular in 29 cases (in 17 transcortical and in 12 transcallosum); subfrontal in 10 cases; suboccipital in 6 cases (5 suboccipital-transtentorial and in 1 suboccipital-supracerebellar); 8 cases transcortical (lobectomy). 20 out of 54 surgically treated patients, were submitted to CSF permanent shunt due to development of hydrocephalus. 4 patients were submitted to surgical implantation of a catheter inside the tumoral cysts. Finally, 20 patients were submitted only to permanent shunt. Out of 61 patients not submitted to direct surgical removal of the tumor, 23 underwent stereotaxic biopsy. Histology was available in 81 cases (70%): 43 neuroepitheliai tumors (among these: 25 astrocytomas, 5 piloeytic astrocytomas, 7 oligodendrogliomas, 3 ependymomas, 2 subependymomas and 1 a malignant plexus papilloma); 4 glioblastomas (5%), I medulloblastoma (1,3%), 1 meduUoepithelioma (1.3%), 1 haemangioblastoma (1.3%0), 1 corioncarcinoma (1.3%), 11 craniopharyngiomas (1.3%), 2 epidermoid (2.4%); 13 were colloid cysts (16.6%), 2 pituitary adenomas (2.4%), and 1 hypophysitis (1.3%). In the remaining cases the presumptive diagnose was: glioma in 22 cases, glioblastomas in 5, lymphoma in 2, metastasis in 1 and meningioma in 1. Direct surgical treatment of tumors resulted in an improvement of the neurological deficits in 68% of cases, no improvement in 13% and a worsening of the clinical symptoms in 4% of cases. 6 patients died: in 4 cases the surgical approach was transventricular. The cause of death were: metabolic derangement and alteration of the level of consciousness due to hyphotalamic and diencephalic impairment (4 cases), meningitis (2 cases, one of which chemical), and coma due to postoperative haemathoma (1 case). The discussion of the results will deals mainly with 1) type of tumors interesting 3d ventricle 2) indications to surgical treatment and surgical approaches 3) results of the treatment.
Surgical approach to the tumors of the trigonal region
Galzio R., Lucantoni D., Magliani V., Tassi G.P., Pineto F.., Bigossi F., Ricci A. (Teramo) The trigonal region is one of the most common sites of origin ofintraventricular tumors; they are frequently benign or of low malignancy; however effective therapeutic intervention is often difficult. In this region we can found choroid plexus papillomas, meningiomas, ependymomas, subependymomas, astrocytomas, angiomas and epidermoid tumors. Hydrocephalus is often associated to these tumors. When these tumors are vascular, they often are supplied by both the anterior and posterior choroidal arteries. The position, type, vascularity and blood supply of the tumor, in addition to the function of adjacent nervous system tissue, are factors that must be considered when planning a surgical approach. Any approach share several features: functional areas should be identified and avoided; early visualization of feeding arteries is important; the border of the tumor is to be reached by tumor resection and retraction rather than by brain retraction to prevent pressure damage in the white matter, which may be partially demyelinated by chronic pressure. Preoperative neurologic findings, such as homonymous hemianopsia, may make a parietal incision or occipital lobectomy exposure more acceptable. No single approach for excission of trigonal tumors is cieady superior to the others alternatives. In this study we present our experience on planning the surgical approach and the surgical results in 10 patients harbouring tumor in the trigonal region (4 meningiomas, 3 choroid plexus papillomas, 2 ependymomas, 1 astrocytoma). Some representative cases, demonstrating the technical surgical management of these lesions, are presented.
Microsurgical treatment of tumors of the thalamus
Occhipinti E., Carapella C.M., Calvosa F., Raus L., Riccio A. (Roma) The thalamus has been longtime considered a critical area, where surgical removal could determine relevant functional damage; nevertheless the introduction of microsurgical techniques has largely increased the feasibility of surgical procedures in the treatment of deep brain tumors. The choice of more adeguate surgical approach and intratumoral removal, using microsurgical techniques, represent good chances to minimize the risk of any functional impairment. Surgery has not only the aim to define the nature of the lesion with biopsy, for complementary treatment planning, but when it is possible, could realize large citoreduction, or better a radical removal, in order to achieve most effective results with multimodality treatment. The exact volumetric definition of the lesion with CT and particularly with MRI gives the opportunity to schedule a precise surgical procedure; on the other hand intraoperative echography may be greatly useful. Our experience shows the feasibility of this kind of surgery. Particularly, we propose to deal with tumors of the pulvinar area, operating by interhemispheric parieto-occipital, parasplenic approach.
The role of neuro-radiological and histological data in the diagnosis and treatment of deep brain tumors.
Carapella C. M., Crecco M., Calvosa F., Caroli F., Occhipinti E., Raus L., Viridi A., Riccio A. (Roma)
Recent advances in neuro-radiological diagnosis of brain tumors, based on the data obtained by CT and MR imaging, not allow to disregard biopathological data of any intracranial expanding lesion, particularly when localized in critical areas or in regions not suitable for surgical approach. As a matter of fact, MRI with Gd-DTPA enhancement plays a crucial role in precise anatomical localization of brain tumors and in the differentiation between neoplastic areas and peritumoral oedema, but frequent reports of rare pathologies or ambiguous characterizations raise the value of stereotactic biopsy in diagnosis ofintracranial lesions, with the aim of more adeguate definition of the therapeutic strategy. The Authors present their experience based on 50 cases of deep brain tumors observed in the last 5 years, submitted to MRI and afterwards to histological diagnosis (stereotactic biopsy or microsurgery) and discuss the informations obtained with the different methods and the importance of biopathological data for specific treatment planning.
34. The stereotactic volumetric information of brain tumors: principles for biopsy or stereotactical resection.
Skrap M., Giamrnusso V. (Trieste)
At present the CT and the MRI unable us to have a very precise information about intracerebral tumor lesions in every cerebral site. They have stimulated a greater sensibility for the rightest choice in the treatment and a more scrupolous study of the radiological documentation, especially if we consider the MRI. They allow us to have a very critical information about the anatomo-surgical aspect of the lesion. In our department we have recently begun to use the Kelly-Goerss stereotactic system which can perform a tridimensional computerized reconstruction of the lesion (based on the CT and MRI radiological information). It allows us to have an accurate preoperative therapy planning. If we compare the volumetric reconstruction based on CT information with the reconstruction on MRI, we get a very precise knowledge about the relationship between the tumor mass and the cerebral tissue, After considering the architectural tumor typization according to the Daumas-Duport classification, we may choose the most appropriate treatment. This choice is based on the combined volumetric information and on its relationship with the surrounding tissue, almost independently of his location. We wish to present here our experi-ence based on 53 cases operated with this approach.
Contribution of intraoperative localization to the surgery of deep-seated brain tumors
Scerrati M., Roselli R., lacoangeli M., Prezioso A., Rossi G.E (Roma) The main problem to be faced during the surgical approach of deep-seated brain tumors is the sparing of the healthy brain tissue. A precise localization and a correct orientation during surgery are necessary to reach this goal. Either stereotactic technique or ultrasonography have been recently utilized as intraoperative guide in the surgical treatment of such tumors. We present here a series of 54 cases operated with the aid of these procedures. In 8 cases (4 anaplastic astrocytomas, 1 pilocytic astrocytoma, 1 oligodendroglioma, 1 glioblastoma, 1 metastasis) we used the stereotactic system of Talairach fitted to the Mayfield headholder (March "88-August '90). The size of lesions varied from 3 to 5 cm of maximum diameter; their location was hemispheric in 7 and thalamic in 1. The ultrasonography was employed in 46 cases (18 metastases, 11 glioblastomas, 4 fibrillary astrocytomas, 4 anaplastic astrocytomas, 3 oligodendrogliomas, 2 pilocytic astrocytomas, 2 ependymomas, 1 cavernoma, 1 lymphoma); with a real-time electronic linear scanner (12 x 44 mm) using a 5 M Hz transducer (Toshiba SAL-38b). The size of tumors varied from 2 to 6 cm of maximum diameter; their location was hemispheric in 33, thalamic/basal ganglia in 8, ventricular in 3 and cerebellar in 2. The surgical resection, usually performed with microsurgical intergiral approach, allowed a gross total removal (S1) in 27 patients (50%), a subtotal removal ($2, residual disease < 10%) in 17 (31.5%), a partial removal ($3) in 10 (18.5%). In six patients (11.1%) we observed the temporary appearance or increase of previous sensory-motor deficits, with a recovery of a KPS never inferior to 0.70 in all of them. Two patients (3.7%) died within one month from operation. Such results seem noteworthy, if we consider that a gross total removal or a minimal residual disease ( < 10%) was obtained in the 81.5% of cases and that two deaths occurred in patients who received only a partial resection. As for the two procedures utilized, both of them showed high reliability in the direct and precise localization of the lesions, always obtained in all cases. The main advantage of the stereotactic technique is the possibility to predetermine the safest approach through a smaller craniotomy. Echography, on the other hand, is by far more practical than the former and thus it can be pre-ferred for the localization of most of the deepseated brain tumors.
Assessment of parameters for staging in
neuro-oncology
Roselli Ro, lacoangeli M., Prezioso A., Scerrati M., Rossi G.F. (Roma) The largerly followed TNM staging system is unfortunately hardly applied in neuro-oncology. Nevertheless brain tumors represent a focal disease which conclude their natural history within the primary inolved organ "... the bottom line is that over 90% of patients with supratentorial malignant gliomas die as result or recurrence at the original site of the tumor" (A.K. Choucair). Consequently, the factor N and M cannot be taken into account for brain tumors which usually do not metastasize. These aspects, together with the recent progress of imaging neuroradiology (CT and MRI), should make the application of a staging system to CNS easier. On the contrary many difficulties still persist, owing to the characteristic biopathology of cerebral tumors and to the peculiarity of the brain itself. Unlike the TNM staging system, we have considered the following parameters: T (TI = T3: tumor extension), G (GI-GIV: grading of anaplasia) and finally S (SI-$3: degree of surgical resection). This latter corresponds to the R factor of TNM system. Three hundred eleven patients with brain gliomas, (162 low-grade tumors and 149 malignant tumors) have been included in our study. All of them underwent surgical procedures, i.e. stereotactic biopsy in 137 and resection by craniotomy in 174. Survival was analyzed using actuarial methods and the statistical significance was tested by "Log-Rank test". Correlations matrix (Pearson) and Cox proportional hazard model were employed in order to assess the relative prognostic value of the above-mentioned parameters. The grading (G) showed a strong positive correlation with survival for all groups considered. For example, in the biopsy series, (group T2), the 5-year survival probability was 85.7% in the GII group, while it dropped to zero in the group Gill. As for t he factor T (surgical series, group GII), the 1-year survival probability of the T2 group was 45% as compared to T3 group in which the survival probability was zero. In the same group, also the S factor showed a significant positive correlation with the survival. The lyear survival probability in fact was 46% in the S I group while it dropped to zero in the $3 group. Again, if we consider the low-grade tumors, we observe a 10-year survival probability of 60% in the S 1 group and of 49% and 38.9% for the $2 and $3 respectively. These data seem to confirm the prognostic relevance of the TGS parameters. Furthermore the multivariate analysis showed a "hierarchy" in their significance: in fact, the G factor was the most important and the only independent variable, followed by T and S respectively, which are, on the contrary, strictly correlated. Obviously a greater amount of cases for each group is needed to validate these data. Furthermore a great attention has to be paid to the objective evaluation of the three parameters with particular regard to the factor S. The end-point of our research will be to define, on the basis of the above-mentioned parameters, different categories suitable for a staging classification in neuro-oncology.
Treatment of inoperable deep malignant gliomas: results and pathological aspects
Soffietti R., Chib A., Giordana M.T., Rudil R., Sales S., Vigliani M.C. Vasario E., Schiffer D. (Torino) Between 1980 and 1991 80 cases of inoperable deep malignant gliomas have been treated by external radiotherapy, associated or not with chemotherapy, and are evaluable. Histological diagnosis was made by stereotactic biopsy and/or autopsy. Radiation was delivered either by conventional (I.7-2 Gy per fraction) or unconventional (3-6.5 Gy) schedules. At progression 4 cases were treated by loco-regional BCNU chemotherapy (carotid and vertebrobasilar circulation).
Results
Radiotherapy is useful in improving the prognosis of inoperable deep malignant gliomas even if the length and quality ofsurvival are generally not as good as in previously resected tumors. Unconventional radiation schedules, employing high doses per fraction, increase the risk of delayed neurotoxicity, whereas the value of intrarterial chemotherapy is to be further investigated. The risk of neurological deterioration during radiotherapy is higher in non resected malignant gliomas (15%): autoptic data suggest that this may be due to an acute increase of necrosis and edema without a true tumor progression. The histological typing in small bioptic specimens is sometimes difficult but is necessary as different types of malignant gliomas (glioblastomas, anaplastic astrocytomas, anaplastic oligodendrogliomas) have different radiosensitivity and, may be, chemosensitivity.
Pathology and survival analysis of 100 hemispheric gliomas of childhood.
Giordana M.T., Chib A., Vigliani M.C..
Cordero di Montezemolo L, Schiffer 1). (Torino)
One hundred hemispheric gliomas of patients below 16 years of age are considered. All the cases were operated. They represent 17% of cerebral tumors of childhood of our series, and 38% of supratentorial cases; 14 belong to children under 2 years of age. The surgical specimens were histologically analyzed. Besides pilocytic astrocytomas, which represent 40% of all cases, other types of astrocytomas, anaplastic astrocytomas, glioblastomas, oligodendrogliomas and mixed gliomas were found. Special attention has been devoted to the vasculature, in particular to endothelial proliferation, mitotic index, nuclear polymorphism, cell density and necrosis as possibile prognostic factors. Survival analysis showed a median survival time of 1710 days for benign oncotypes and of 183 days for malignant ones. The prognostic value of different histological and clinical factors was obtained by means of multivariate analysis.
Melatonin and pineal tumors
Grimoldi N., Tomei G., Spagnoli D., Lucarini C., Villani R.M., Losa M., Stankov B., Lucini V., Masini B., Mercatelli C. (Milano) Tumors of the pineal gland includes tumors of different hystological types. In order to evaluate the hystology of these tumors a particular attention is generally assigned to serum and CSF determination of umoral markers as Alfa-FP, [~-HCG and CEA. The aim of this study was to verify 1) whether exists a relationship between tumors of pineal region and modification of melatonin circadian secretion 2) whether the melatonin determination may be used as a specific preoperative marker for some oncotype. Five patients with pineal tumors were admitted at the Neurosurgical Dpt. of the University of Milan between July '89 and Dec. '90; 3 were males and 2 were females; their age ranged between 20 and 52 years. In all patients we performed: a) preoperative determination of serum and CSF levels of Alfa-FP. Beta HCG and CEA, 2) pre and post-operative determination of circadian rythm of melatonin, 3) pre and postoperative determination of GH and cortisol serum levels. To evaluate the presence of modification of the rythmic produciton of melatonin, GH and cortisol, blood have regurarly been drown at 8 am, 2 pm, 8 pm and 2 am, for 4 consecutive days. In the night, patients were kept in the dark or exposed to a red light that does not inhibit the melatonin secretion. Blood samples were immediately centrifugated and serum refrigerated at -30~ Serum and CSF melato-nin levels were assessed with RIA method according to the procedures described by Fraser (1983) . All patients were submitted to total removal of the tumors, as confirmed by post-operative CT and NMIL In order to detecte the melatonin receptors, fragments of tumors were immediately refrigerated at -80~ Hystology revealed 2 pineocytoma, 1 germinoma, 1 pineoblastoma and 1 lymphoma. Immunochemistry of all tumors, except the lymphoma, was performed with policlonal antibodies for melatonin, kindly provided by Brown and Ravault-Tillet. In all patients a preoperative modification of melatonin circadian rythm and secretion was observed. In pineocytomas, melatonin levels were reduced. Melatonin circadian rythm was still preserved in one patient, while in the other there was a shift of nocturnal peak that was anticipated at 8 pm. In patients with pineoblastoma and lymphoma, the melatonin circadian rythm was abolished and the melatonin levels were undetectable. In patient with germinoma, an exaggerated metatonin secretion associated with abolishement of the circadian rythm were observed. In all patients, CSF levels of melatonin were below 10 pg/ml, with the exception of patient with germinoma in which melatonin levels were extremely high (> 900 pg/ml). Serum and CFS levels of Alfa-FP, Beta HCG and CEA were normal before and after surgery. Preoperative Gh and cortisol levels were in normal ranges, except during desametasone treatment. Melatonin receptors were absent. Postoperative circadian rythm and secretion of melatonin were abolished in all patients. All tumors, except the lymphoma, were tested with sera against melatonin. In pineocytoma and pineoblastoma immunohistochemical determinaton of melatonin were negative. Only the cells of germinoma had a significant reaction for both antisera. The limited number of our cases, do not allow to definite results. However it seems to there is the evidence or a relationship between secretion of melatonin, oncotype and tumor malignancy. In patients with pineocytomas the reduced levels of melatonin secretion and the alteration without abolishement of circadian rythm suggest that the tumor has spared a part of pineal gland. In patients with pineoblastomas and lymphoma melatonin was not detectable as the tumor growth has led to complet pineal destruction. In patient with germinoma an exaggerated secretion of melatonin associated with the abolishement ofthe circadian rythm was observed and this suggests the hypothesis that the tumor is directly responsible for melatonin production. Positive immunohistochemical reactivity of tumoral cells to antisera against melatonin supports this hypothesis.
Prognostic factors in intracranial ependymomas
Vigliani M.C., Chib A., Giordana M.T., Palma L., Pezzulo T., Polio B., Rudlt R., Soffietti R., Schiffer D. (Torino, Siena, Milano) Ependymoma is considered a quite benign tumor, even if is characterized by a variable clinical behaviour. Still now no clinical and pathological features correlated with prognosis have been identified. The existence of an anaplastic variety, and the opportunity of a differential therapeutic approach to this form, is still debated. We have performed an analysis on 173 cases of intracranial ependymomas, either of chidhood or of adulthood, collected from several neurosurgical departments. Different morphological and clinical factors have been correlated with survival both individually and in a multivariate analysis. In supratentorial ependymomas only cases characterized by very high cell density and high number of mitoses (> 20 x 10 HPF), showed statistically significant shorter survival. The association of these two factors identity a subgroup of tumors with a poorer prognosis and an aggressive, "malignant" behaviour. No prognostic factors have been found for infratentorial ependymomas, also for the limited number of cases. We have taken into account and analyzed the relationship between histological features and some clinical characteristics of the tumor: age, clinical history, duration of symptoms, pre-and post-operative neurological status, extension of surgical removal, association of radiotherapy, pattern of recurrence.
Localization stereotactic systems and theory of trajectories
Piovan E., Pasoli A., Gerosa M., Foroni R:, Beltramello A., Mazza C., Vivenza C., Bricolo A., Benati A. (Verona) Summary -By april 1990 neurosurgical stereotactic procedures are currently performed in Neurosurgical Department of Verona City Hospital. The stereotactic apparatus requires three components: an image-generation device, a mechanical frame and, last, a procedure able to transform image-system coordinates in frame positions. Invariably, our procedures were performed using the Leksell frame associated to C.T. scanner equipment. In stereotactic neurosurgical procedures, the need for avoiding intracranial important structures (ventricular system, tentorial tent...) often arises: nowadays there are many computer real-time systems able to directly display on the screen the various anatomic structur-es reached by the probe as it advances along the chosen trajectory. Not being available in our early experience any form of post-processing system, the target coordinates were generated using as a basis the orthogonai axis passing by the Leksell plane, directly derived from the axial pictures. Our stereotactic localization system developed in our Department based on Euclidean geometry and plan trigonometry, in order to calculate the arch and probe tilt, is presented and analyzed.
User friendly software for stereotactic brachitherapy
Foroni R., Pasoli A., Gerosa M., Piovan E., Nicolato A., Vivenza C., Mazza C., Bricolo A., Benati A. (Verona) Widely used in the last years the stereotactic Brachitherapy is one of the most valid approach for treatment of unresectable brain tumors. The stereotactic procedures of radioactive source implants are designed to take the great advantages of Imaging of CT or NMR, but not the radiotherapy features related to the exact 3-dimensional calculation of dose. Aim of our work is devoted to perform a software procedure to develop an integrated treatment planning of dose calculations to superimpose the isodoses levels on CT images trasferred on PC or Mini Graphic work station. The program print out the desired dose rate to target volume for Iodine 6702 implants (but can support any potential X-Ray source). Written, as ongoing project, in C language user friendly is running on particular hardware configuration of 1860 RISC Processor Board of Mi-croWay Family (40 MHz Clock speed, 8-32 Mega RAM) connected to Matrox Board via Internal Bus.
llz s brachitherapy in neuro-oncology. Radioprotective measures
Pasoli A., Foroni R., Gerosa M., Piovan E., Nicolato A., Vivenza C., Mazza C., Bricolo A., Benati A. (Verona) During delivery of I~25 brachitherapy for treatment of brain tumors there is an exposure level of X-ray in and around the patient and consequently to the unit staffworking in the treatment room. The exposure level is limited to the necessary procedures of loading the radioactive source during the patient treatment session. Aim in this work is related to monitor the various exposure rate during the loading process and to perform an idoneous shielding for X-ray atten-uation. The exposure level rate of authorized personnel are summarized for the various organs (eyes, hands, head...), all the data reported is performed with radiation staff of Neurosurgery Department, University of Verona, during a stereotactic treatment of 6702-1125 seeds implants. Review of personal exposure monitors have not detected any particular increasing risk factor, because of the lower exposure level of crew wordking in the treatment room during brachitherapy compared to one working with usual X-ray machinary.
CT as an alternative to NMR in the diagnosis of brainstem tumours
Daidone R., Agati R. (Bologna)
Nuclear Magnetic Resonance is the first choice imaging technique in the diagnosis and display of tumours in the posterior cranial fossa, especially the brainstem. However NMR equipment is not readily available nation wide and there are long waiting lists in the few well-equiped centres. For this reason, accurate and prompt diagnosis of these tumours is required by CT, a much more widely available technique. The cases presented show that appropriate CT scanning techniques fulfill diagnostic criteria and offer satisfactory tumour demonstration. M., Montemaggi P., lacoangeli M., Roselli R. (Roma) The traditional treatment of malignant cerebral tumors (surgery, radiotherapy and chemotherapy) is not able to prevent the rapidly fatal outcome of the disease. The reasons for treatment failure are either the difficulty of surgery to remove the infiltrating elements at the tumor periphery (BAT) or the radio-chemo resistance of such neoplasms. The increase of the radiation dose to the tumor, on the other hand, is directly related with the risk of secondary brain edema and coagulative necrosis. The possibility to overcome such problems can be offered by utilizing the brachytherapy followed by the resection of the irradiated volume, thus making the high dose regimen tolerable. On the basis of these theoretical assumptions, we planned a therapeutical trial considering two arms: in thefirst, brachytherapy was utilized for the treatment of recurrences, according to the following scheme: surgery, external radiotherapy, brachytherapy on the recurrence and surgery again; in the secondarm, brachytherapy was used as the first treatment for newly diagnosed tumors ("upfront"), as follows: stereotactic biopsy, bracbytherapy, surgery and external radiotherapy. Malignant supratentorial cerebral tumors, surgically accessible and with volume not greaer than 35 cc, in patients with KPS not lower than 0.70 are the conditions of eligibility for the study. The efficacy of the treatment is evaluated on the basis of the duration of the survival as well as of the time to progression or to recurrence. Kamofsky performance status, neurological and neuroradiological features are also analyzed. The study is begun just for a short time and only the first arm has been considered so far. Therefore we will present and discuss here mainly the methological aspects of the protocol and the preliminary results obtained by its application.
Combined radio-surgical treatment of malignant cerebral tumors. Fase I/II study
Scerrati
Radioimmunotherapy of brain malignant glioma by direct intratumour injection of radiolabeled BC-2 monoclonal antibody.
Arista A., Sturiale C., Riva P., Moscatelli G., Donati R. (Cesena) The use of radiolabelled Monoclonal Antibodies (MoAbs) raised against neoplastic tissue associated antigens may be of value in oncology clinical practice both for diagnostic and therapeutical purposes. Current management of brain gliomas gives unsatisfactory results as to length of survival; to improve this, in recent years, several complementary techniques have been introduced in an attempt to treat recurrences as radically as possible (interstitial brachytherapy, fractionated radiotherapy,local hyperthermia, local instillation ofantiblastic products, fast neutrons...) On the basis of experimental works and of preliminary clinical experiences of other Centers (Sheffield, U.K.), we have treated 11 patients with glioma recurrences by means of direct intralesional injection of the antiTenascin MoAb BC-2 labelled with 1-131. Tenascin is a high weight glycoprotein expressed by the stroma of several tumours: breast, ovary, prostate...; in particular it is present in the stroma of malignant g.liomas whilst it is not found in normal cerebral tissue. MoAb BC-2 recognizes a tenascin epitope thus specifically targeting glial tumours. We adopted the intralesional route because it is more favourable as compared to the intravenous or intraarterial routes leading to greater MoAb uptake in the lesion. Both systemic and local toxicity resulted negligible. Average BC-2 MoAb uptake on the tumor after 24 hours was 4.90% per gram and MoAb effective half-life in the neoplastic tissue was about 66.5 hours resulting in a radiation dose to target tissue of 36.5 cGy per MBq of injected 1-131. By contrast, both the normal brain and the major organs resulted spared. The administered dose ranged from 0.5 to 3 mg of MoAb. Cumulative radiation dose ranged from 5000 to 15000 cGy, calculated according to MIRD system. Serial planar and SPECT immunoscintigraphies were run from 10 minutes to 240 hours after administration. Side effects were rare and never life-threatening. A short-term follow-up and preliminary results are presented.
Surgery with concurrent chemo-and radiotherapy for malignant cerebral gliomas. Preliminary findings of a pilot study
Zampieri P., Brandes A., Zorat P.L., Paccagnella A., Rigon A., Berti F., Scelzi E., Padoan A., Alessio L., Calzavara F., Fiorentino M.V., Mingrino S. (Padova) A multidisciplinary study on the concurrent treatment of malignant gliomas was begun on April 1st '91 by the departments of Neurosurgery, Oncology and Radiotherapy at the University Hospital of Padua. Eligibility. Histological diagnosis of anaplastic astrocytoma or glioblastoma; age between 15 and 70 year; performance status (Karnofsky score) > 50; no associated pathologies to controindicate chemo-and/or radiotherapy. Study design. All patients undergo surgery as radical as possible followed by BCNU 150 mg/m 2 iv. after 7-9 days. Thirty days later, radiotherapy is begun with 1.8-2 Gy/day for 5 days a week on restricted fields up to 60 Gy, with simultaneous administration of 200 mg/m 2 Carboplatinum on day 1 and 50 mg/m 2, VM26 on days 1,2 and 3; the chemotherapeutic cycle is repeated 3 weeks later. Aims of the pilot study. To verify the short-and longterm toxicity of the combination of chemo-and radiotherapy. Evaluation of response and toxicity. Response is evaluated on CT scans and toxicity according to the WHO criteria. The preliminary results of the pilot study are reported. Rudlz R., Chib A., Sales S., Pagni CA., Vasario E., Medina C., Meineri P., Perla F., Soffietti R., Schiffer D. (Torino, Cuneo) Selective manipulation of metabolic pathways is a new therapeutic modality for brain tumors. Lonidamine (LND) has been shown to reduce the energetic metabolism of glioma cells and would thus interfere with cell growth and recovery from damage due to RT. A multicentric randomized trial has been organized in Northwestern Italy by the II Dept. of Neurology of the University of Turin to evaluate the efficacy and toxicity of lonidamine in association with RT in histologically confirmed malignant gliomas. On 15 June 1991, 47 patients are evaluable: 26 received RT alone (60 Gy) and 21 received RT + lonidamine (450 mg/ die). Median survival is 435 days for patients receiving LND and 330 days for those receiving only RT, with 75% and 46% alive at 1 year: however, differences are not statistically significant. Eighteen patients in the LND group are evaluable for toxicity. LND was well tolerated in 9 patients, while 9 developed side-effects, leading to drug withdrawal for liver toxicity in only 1 patient. Most common side-effects were myalgias, followed by fatigue, nausea and anorexia. Less frequent were testicular pain, somnolence and ocular and hearing alterations. EMG values and CPK blood levels were always normal in patients receiving LND.
Radiotherapy (RT) versus RT + Lonidamine in malignant gliomas: interim analysis of a phase llI study
Chemotherapy for malignant gliomas after surgery
Boiardi A., Silvani A., Milanesi I., Giovagnoli A.R., Chiapparini L., Franzini A. (Milano) The effectiveness of radiotherapy and chemotherapy (BCNU carmustine) has been established in treatment of gliomas. Addition of BCNU increased the proportion of survivors of 18 months from 4 to 19% Nevertheless a common nihilism persist in the neurological community. We believe that it is self-defeating. We had considered the survival time (ST) of 42 GBM patients (grading 4 WHO) operated on in our Institute between May 87 and May 89. After surgery all patients underwent accelerated splitting radiation therapy protocol (4200 cGy) and chemotherapy scheduling different drug combination (CDDP and CBDCA, VPI6, BCNU). Each patient was treated with a second chemotherapy protocol at tumor relapsing. Five patients with life expectancy less than 2-3 months and Karnofsky performance status less than 50 did not enter this study. Eleven patients after repeated courses of chemotherapy underwent twice surgery. Survivors at 18 months and 2 years were 52,6% and 18% respectively. Furthermore a pattern of 10 patients out of survivors at 18 months had been investigated by some neuropsychological tests to value their understanding, intelligence, attention, memory and visuo-motor performance. Data showed a good life quality. Tumor was not removed in seven patients who underwent only biopsy. These patients showed median ST of 14.3 months after repeated chemotherapy protocols. During the same time 30 other GBM patients were operated on in our surgery department, but owing to different reasons, they had not been followed after surgery in our Institute. Ten out of these patients did not enter the study because their life expectancy was less than 2-3 months. The median ST was 52 weeks, survivors at 18 months and 2 years was 16% and 10% respectively. We are thinking that repeated surgery and protracted chemotherapy cycles could be effective to extend the ST in GBM patients yet considering prognostic factors such as age and performance status.
Neoadjuvant chemotherapy in recurrent glioblastomas (GBM) treatment
Boiardi A., Silvani A., Croci D., Broggi G. (Milano) Gioblastoma usually recurs from 6 to 11 months after surgery, radiation and chemotherapy. Historically the median survival time is known to be less than 12-13 months. The inevitability of tumor recurrence and the often dramatic neurological deterioration that follows, pose the dilemma of choosing among a second subtotal excision and chemotherapy, chemotherapy alone or the grim acceptance of inevitable death. The results of reoperation are generally regarded as unsatisfactory in terms of both extension and quality of life. Reoperation has been proposed only in very selected cases, even though its value has never been thoroughly investigated. The aim of our study was to promote a propitious condition for a second tumor removal in selected recurrent GBM patients, who still have acceptable life quality and rather long disease free. Entered this study 18 recurrent GBM patients none of them at the beginning showed the conditions we had established for a second tumor resection. As concern the chemotherapy protocol, we experienced high doses of methotrexate associated with 5-fluorouracile, delivered when tumor relapsed. Patients responder (R) were 27.7% and on a stable disease (S) 33.3%. Five out of these patients after two cycles of chemotherapy achieved the conditions for a second surgery. All these patients survived more than 18 months. The median ST of not responder patients was 58.8 weeks against 82.6 weeks of reoperated on patients (P < 0.05). Five out of 18 (27%) of patients owing to chemotherapy protocol underwent a second tumor removal with an adjunctive disease free of 23 weeks of good quality of life.
Adiuvant chemotherapy with carboplatin in the treatment of malignant brain tumors: a phase I and II
Maleci A., Oppido P.A., Bardella L., Dilorenzo N., Cantore G.P. (Roma) We refer our experience in the treatment of malignant brain tumors (III and IV WHO) with carboplatin. The drug was administered e.v. at a dose of 750 mg/m ~, fractionated in two consecutive days. Our series consists of 45 patients: 31 glioblastomas, 11 anaplastic astrocytomas, 2 medulloblastomas, and 1 multiple metastasis from ovarian carcinoma. The tolerance to the treatment was evaluated by means of clinical and haematological exams; in no case a particularly severe adverse reaction (IV grade according to Miller et al.) was observed; only once the severity of thrombocytopenia led to a decrease in the drug regimen. As far as the therapeutic results are concerned, only the 31 glioblastomas were considered. The patients were subdivided into 4 groups: -patients with a totally removed giioblastoma where the radiotherapy was administered after a first course of chemotherapy.
patients with a totally removed glioblastoma, where the radiotherapy was administered before chemotherapy.
-patients with a partially removed or recurrent glioblastoma, where radiotherapy was administered after a first course of chemotherapy.
-patients with a partially removed or recurrent glioblastoma, where radiotherapy was administered before chemotherapy. The results suggest that, expecially in the first group of patients carboplatin might represent a significative tool to increase survival in malignant glioma patients.
Superselective intraarteriai chemotherapy (SIC) with carboplatin (CP) in brain malignancy: a phase I-II prospective study
Cartei G., Lavaroni A., Clocchiatti L., Signor M., Vigevani E., Janes P.P., Vindigni G., Fabris G., Zanotti B., Leonardi M. (Udine) Patients with Primary Brain malignant Tumors (PBT) and with Brain Metastasis (BM) continue to have a poor prognosis. Encouraging results have been reported with Intraarterial (cerebral) (IA) infusion of various antineoplastic compounds, such as Platinum and BCNU and others. CP is a less toxic compound of Platinum; it was used via SIC for BPT or BM: From Febr. 1990 to May 1991, 25 patients were studied: 13 females, 12 males, aged 17 to 70 yrs (mean 52, median 54). Thirteen had glioblastoma, 5 astrocytoma and 7 had BM (3 from lung, 2 from breast, 1 from kidney and 1 from unknown primary cancer). Previous therapy in PBT was: a) radical surgery with recurrence 5, partial surgery 8; b) radiotherapy 4; c) systemic CH 4; d) systemic CH in 5 BM. CP was given alone or in association with systemic (s) CH (CDDP, BCNU; VM26, Hydroxyurea), by means of an angiographic injector pumping system, diluted in 250 ml over 30 minutes. Starting dose was 100 mg every 2 (CP alone) or 4 (CP + sCH) weeks, with dose escalation of 50 mg; actual maximum dose is 400 mg and escalation is progressing. Cycles were 77, I to 6 in each patient (median 3). No pt has been lost at the follow-up and all are evaluable for toxicity; 19 are also for response having received at least more than 2 month therapy. 8 patients had CP and sCH because of glioblastoma 5 (2 Stable Disease SD; 2 Partial Remission PR and 1 Progression PRO); astrocytoma 3 (2 PR, I PRO). 11 pts had CP alone for glioblastoma 5 (4 SD and 1 PRO), astrocytoma 1 (PRO) and BM 5 (4 SD and I PR). Response duration in 19 pts: the 9 SD was 9 to 46 weeks (median + 24.2); the 5 PR was 42 to 67 weeks (median + 50.6). Apt with PR reached the surgical operation and he remains in Complete R + 6 months. Gastrointestinal, bone marrow, kidney, PNS toxicity was almost absent; two pts had temporary reversible hemiparesis without preclusion for further IA-CP. Results are encouraging and the study progresses. Sales S., Bradac G.B., Riva A., Rudit R., Soffietti R., Schiffer D. (Torino) Intraarterial BCNU has shown activity against malignant giiomas, but it is associated to a risk of delayed leukoencephalopathy. Neurotoxicity from BCNU has been related to the association with RT, to the use of ethanol as a diluent, to the drug itself and to slow infusion. The aim of this study is to reevaluate the efficacy and toxicity of intraarterial BCNU in recurrent malignant gliomas after administering low doses of the drug (160-180 rag/m2), avoiding ethanol (dextrose 5%) and employing a superselective and fast infusion (15 ml/min). 16 patients have been treated with selective infusion in the supraophthalmic carotid artery (SCA) (7 cases), in the SCA and middle cerebral artery (6 cases), in the SCA and posterior cerebral artery (2 cases) and in the basilar and posterior cerebral artery (1 case). We observed 3 partial responses (3 cases ofanaplastic astrocytoma), 7 sta-ble diseases and 6 progressions with median survival of 27, 24 and 8 weeks. No systemic or visual toxicity has been observed, and only transient neurologic disturbances in 4 cases and a suspected leukoencephalopathy in 1 ease. In conclusion: the technique of superselective intracranial infusion seems relatively safe and may be used for treatment of tumors supplied by both the anterior and posterior circulation. 54. Current applications of implanted system for intrathecal chemotherapy in malignancies protruding and spreading into CSF pathways. lacoangeli M., Leone G., Pagano L., Prezioso A., Roselli R., Scerrati M. (Roma) There is an increasing interest, both clinical and experimental, in chemotherapy for malignant intracranial tumors. Several data suggest that a method to increase Ioco-regional drug delivery, such as local intratumoral or post-surgical intracavitary administration, intraventricular infusion and intra-arterial route, can result more effective and less toxic than systemic chemotherapy. The rationale for, methodology of and preliminary experience with implanted system for intraventricular chemotherapy (IVC), in the treatment of intracranial tumors, protruding and spreading into CSF pathways, are described. The rationale is based on the capability of IVC to circumvent the blood-brain barrier (BBB), which plays an important role in the lack of drug effectiveness in systemically administered chemotherapy. The criteria to select drugs for CNS is based on the observation that water-soluble drugs poorly cross the BBB, compared to lipophilic compounds, but they offer better conceptual advantage regarding pharmacokinetics when injected intrathecaUy. Initially our experience was limited to patients with systemic malignancies of lymphoreticular origin metastasizing to CNS. Recently we have trated also patients harbouring primitive highly malignant cerebral tumors, strictly related to and spreading into CSF pathways. This choice is necessary if we consider that ependymal layer is relatively impermeable and the diffusion from ventricular surface into brain tissue is only millimeters. This lack of penetration may explain the therapeutic failure, in the treatment of intrinsic brain tumors. Eleven patients, with neoplastic relapse for acute lymphocytic leukemia (5), acute myeloid leukemia (1), non-Hodking lymphoma (1), PNET (3) and germinoma (1) were treated with IVC. Radiotherapy was carried out in all patients with primitive brain tumors and surgical resection in three of them. A Rickham reservoir connected to a silastic tube placed in the frontal horn of the lat-l'he Italian Journal of Neurolagical Sciences eral right ventricle was used. There were no immediate surgical complications related to the implantation of the system. As late complications, we observed CSF leakage (after 51 months) and staphylococcal meningitis (after 6 months) in two patients respectively. We have used the methotrexate associated in some patients with cytosinearabinoside, that may enhance the antifolate effect of the former. Five patients are alive and disease-free (18-50 months survival from IVC), four patients died between 8 and 38 months from IVC, two patients are still under standard induction treatment, with remarkable reduction of tumor burden. Although preliminary, this data seem to indicate that IVC, can be a safe and an effective method in the multimodality treatment of highly malignant brain tumors protruding and spreading into CSF pathways.
Superselective intraarterial BCNU in recurrent malignant gliomas: a phase I-II study
High dose carboplatin and etoposide in the treatment of childhood brain tumors. Results of treatment and follow up.
Castello M.A.. Clerico A.. Dominici C., Schiavetti A.. Properzi E., Bartolo'.zi S., Ragni G., Trapasso E.. Cappelli C.A. (Roma) Since December 1987 we started a pilot study aimed at evaluating in children with primary brain tumors the toxicity and the therapeutic activity of the association carboplatin (500 mg/ mq/day on days 1 and 2) and etoposide (100 mg/ mq/day on days 1,2 and 3). Courses were repeated every 21-28 days. Twenty patients of various age and sex were entered in the study: 9 with medulloblastoma, 3 with high-grade astrocytoma, 6 with low-grade astrocytoma, 1 with ependymoblastoma and I with embryonal carcinoma. Eight of them, including 5 medulloblastomas, were pretreated with radiotherapy. After two or four courses, 2 completed responses (CR), 10 partial response (PR), 7 minor responses (MR), l stable disease (SD) were obtained. Therefore, the overall response rate (CR+ PR) was 12/20 (60%). As far as the histology is concerned, the disease specific response rate was 8/9 (89%) in medulloblastoma, 2/3 in high-grade astrocytoma, 0/6 in low-grade astrocytomas, 1 / 1 in ependymoblastoma, and 1 / 1 in embryonal carcinoma. No treatment-related death occurred. The main side effect was myelosuppression, but it was easily controlled by antibiotic and trasfusional supportive therapy. Following chemotherapy all patients were treated with conventional radiotherapy and surgery that previously could not be practiced. After 6-42 months from the beginning of study 10/20 patients (6 medulloblastomas and 4 astro-cytomas) are alive. Particularly 4 medullobastomas are in complete remission over one year from the end of treatment. In conclusion these findings confirm that this regimen is very effective in brain tumors with high malignant behaviour and especially in meduiioblastoma.
Treatment of medulloblastomas in adults
Krauseneck P., M~ller B. (Bamberg, Wurzburg) During the last 10 years we treated 17 consecutive adult patients (age 17-49 y. 12 m, 5 f), 12 with desmoplastic, 5 with classic medulloblastomas. Treatment consisted of resection (11 x "total", 6 x subtotal), irradiation (11 x neuraxis (NAI), 2 x whole brain (WBI), 4 x fossa post.) and i.th. chemoprophylaxis (12x) with Cytosine Arabinoside (ITH). Intravenous chemotherapy was done in relapses only (6x). Results. No local recurrences after radiotherapy; 10 x CSF dissemination; 8 x solid metastases (3 x supratentorial, 2 x spinal; 2 x bone metastases). Median survival > 2 years (range 2m -10 y). 2 pts. live for more than 9 years after surgery, NA ! +/-ITH. 2 of the 6 relapsing pts, achieved complete remission after i.v. plus i.th. chemotherapy. 4 of the 10 CSF relapses occured in spite of NAI + ITH. Conclusion. This series demonstrates that local tumor growth is controlled by high radiation dose (54-60GY) whereas the problem of CSF and solid metastases remains unresolved. Even the combination of NAI + ITH could not control spinal relapses, but 2 pts. suffer from radiation induced myelopathy. Therefore the concept of NAI seems questionable, also because chemotherapy will be restricted by impaired bone marrow capacity. Wc consider high-dose local irradiation of the tumor region combined with i.th. chemoprophylaxis and an intensive adjuvant systemic chemotherapy advisable in the treatment of medulloblastomas in adults.
Radiosurgery in medulloblastoma. A new perspective
Valentino V. (Roma)
It is well known today that the term "radiosurgery" refers to closed-skull stereotactic irradiation in a single high dose (SHD) directed at an intracranial target measuring 25mm or less in average diameter. From March 1984 -March 1990 patients with intracranial tumors underwent stereotactic radiosurgery, among which there have been 6 medulloblastoma. We felt radiosurgery was indicated in these patients, as prophylactic postoperative full CNS-RT and chemotherapy had been unsuccessful to prevent local recurrence and cerebral metastases of the tumor. For the stereotactic determination of the coordinates of the target we used the atraumatic and reproducible Greitz-Bergstr0m fixation head device. Irradiation was performed with a 6 MeV linear accelerator through one coronal and multiple sagittal arches, using circular collimators from 10-25ram. Patients were accepted for treatment even if the tumor measured more than 25ram on the basis of the following criterion: according to the volume and configuration of the tumor a SHD is directed at one or more selected targets, provided that a computer with specially developed software is used for checking the isodose distribution. Then, the minimum tumor-dose ranging between 10-20 Gy is integrated, depending on the precise analysis of the tumor response. Age at diagnosis of the patients ranged from 2-16 years. In 1 patient radiosurgery was performed on previous incomplete resection of the tumor. Two patients were referred for local recurrence, 2 for local recurrence and metastases, and 2 for metastases. Follow-up enhanced CT imaging studies showed complete regression of the tumor in 4 patients and incomplete regression in 2. Four patients are still alive with a follow-up ranging from 20-76 months and a post-RS pediatric Karnofsky ind. between 80 and 100 per cent. Two patients died for lepto-meningeal dissemination 4 and 9 months after radiosurgery in spite of the disappearance of the intraeerebral lesion. Radiosurgery has shown to be a new perspective to prolong survival of patients with medulloblastoma in cases ofresurrence or metastases even after postoperative full CNS-RT, and chemotherapy has been given. Full CNS-RT, however, is not without risk in children as it may reduce intellectual and physical development. Thus, considering the survival and quality of survival, especially after removal of the tumor, the advantages of limiting conventional RT to the tumor area have been emphasized. With these principles in mind, the application of postoperative radiosurgery in medulloblastoma may be postulated as a primary treatment.
Chemotherapy for primary lymphoma of the central nervous system.
Silvani A., Allegranza A., Boiardi A. (Milano) Primary cerebral Non-Hodking's lymphomas (NHL) are rare lesions, estimated to be less than I% of all intracranial neoplasm and only 2% of all malignant lymphomas. Most cases, when untreated, pursue a progressive course and die in a little time after the beginning of symptoms. The NHL is radiosensitive and radiotherapy increases overall survival. Longer survival, ranging from 5 to 10 years after diagnosis have been occasionally reported. In this study 5 patients (HIV/-) with NHL, with CNS origin were treated with M-BACOD regimen every 21 days for 2 cycles followed by radiotherapy. Radiotherapy started 1 month after the end of second M-BACOD cycle. These 5 patients were submitted to the usual dinical-pathologic staging for NHLs. Both the Kiel classification and Working Formulation were used for histopathological classification. All patients underwent biopsy 3/5 were centroblastic, 1/5 immunoblastic and 1/5 lymphoblastic. Responses were based on NMR evaluation, performed after 2 cycles of chemotherapy and before irradiation. Objective responses obtained were: 4/5 complete remission and 1/5 partial remission. In one out of 5 patients responder malignancy relapsed 11 months after histological diagnosis, Time To Tumor progression did not occurs in one year in all other cases. Toxicity was mild, but one patient developed a necrotizing leukoencephalopathy and he died 16 months after diagnosis. In conclusion our preliminary results confirm the effectiveness of M-BACOD protocol. We think that M-BACOD protocol could be delivered as neoadjuvant chemotherapy to allow to reduce radiation rate. A better definition of the possible role of chemotherapy requires further controlled studies to explore the protocol's activity in combination with radiotherapy. Zappoli F.., Farina L., Gaetani P., Danova M., Lombardi D., Rodriguez y Baena R. (Pavia) Prognosis of malignant neuroepithelial tumors still remains lethal, whethever multidisciplinary adjuvant treatments have provided a significant improvement in overall outcome of these patients. In order to obtain significantly longer survival rates, recently, new administration techniques for chemotherapeutic agents have been proposed: superselective intra-arterial administration allows to deliver in the tumoral bed significantly higher doses of the drug, with a significant reduction of collateral effects. Thereafter, even if this concept appears to be reliable, any definitive conclusion can be drawn, at moment, because of the absence of randomized controlled studies which support this hyphothesis. Our group has used superselective intra-arterial route tbr treatment with Carboplatinum, a cis-platinum derivative with an analogous cytotoxic activity and less neuro, oto and renal toxicity. In a pilot study, we have treated 10 patients operated on for malignant neuroepithelial tumors (7 glioblastomas, 3 anaplastic astrocytomas) with superselective intra-arterial administration (in about 30 minutes) ofcarboplatinum (300 mg every 15 days, until 5 cycles have been completed). The results of this study have shown a good response in over 75% of cases (as evaluated with CT findings), with significant improvement of neurological and performance status, in absence of evident toxic effects. Thereafter, traditional treatment schedules consider that chemotherapy had to follow radiotherapy: there are experimental evidences that radiation treatment causes a significant endothelial and avventitial proliferation with ialinization and thickening of vessel wall and the consequent reduction of permeability and diffusion capacity of chemotherapeutic agents. In order to study this important aspect, we have organized a multicentric study which consider immediately after surgery the first cycle of superselective intra-arterial chemotherapy with carboplatinum and VP 16, and epipodophiiio toxinum derivative which exerts a sinergic effect with platinum derivatives. Both drugs will be administered every 4 weeks at the dose of 200 mg each, for a total number of 5 cycles. After the second cycle will be completed, patients will be randomized for immediate or delayed radiotherapy. Patients will be controlled at any cycle with clinical, radiological (CT) and laboratory investigations. The aim of the present study will be to verify; (a) the efficacy of superselective intra-arterial route; (b) feasibility and validity of chemotherapy before radiotherapy; (c) the duration and quality of survival.
Superselective intra-arterial polychemotherapy in adjuvant treatment of malignant neuroepitheliai tumors
Gliomatosis cerebri diffusa: diagnosis with biopsy only?
Toso V., Rizzuto N., Maccarrone G., Simonati A., Cagnin G, Cavallaro T., Nen S. (Castelfranco Veneto, Verona) The deep tumors diagnosis is facilitated by stereotassic biopsy. However thinking that the neuroimaging techniques are always able to distinguish the tumors from other lesions is not correct. In certain cases is necessary to take up a wide bioptic fragment. A case is presented where only the autopsy revealed the diagnosis in spite of the amount of diagnostic procedures unsuccess fully carried out.
A 67 year old woman with a previous history of mild hypertension and a 3 years before spontaneously regressed leucopenia, was admitted because a waking-sleeping rate derangement and a left side hemiparesis and hemineglect. The clin-ical course was progressive and after 5 months the patient was tetraplegic, dysphagic and anarthric.
Only the vigilance and the facial and ocular mobility were still preserved. Three cerebral CT scans were performed and confluent hypodensities of the white matter especially in the frontal and parietal regions, unchanged from the contrast, were showed. The SPECT, two times performed, found a radionuclide hypocaptation on the same cerebral areas. The cerebral RMI showed diffuse hypeducent areas particularly in the white matter of the right parietal region. The EEG was normal and CSF examination missed to find batteria, mycetes, neoplastic cells and globulins intrathecally synthetized. The patient died from a hemorrhagic broncopnemonia while she was still waiting for cerebral biopsy. On sections of the brain a bilateral greysh infiltration of the centrum semiovale and a swollen pons were seen. The neoplastic infiltration sparing the brain anatomical architectures and the low degree of vasal neoformation account for the non specific pattern of the neuroimaging techniques. We therefore wonder if cerebral biopsy only is diagnostic is similar cases.
Primary spinal extradural lymphomas: surgical experience in 12 cases
Tacconi L.. Artico M., Salvati M., Raco A. and Ciappetta P. (Roma) Primary spinal extradural lymphomas are relatively uncommon lesions occurring in adults without sex preference. We present a series of 12 surgically treated patients with primary spinal extradural lymphomas. 7 patients were male and 5 fermale, age range 21-66 years (mean 51), with clinical onset marked by signs of spinal cord compression in all cases. The majority of patients showed severe paraparesis with sensory disturbances. Sphincteric disturbances have been observed in 4 cases. No systemic illness was discovered. Preoperative plain X-ray films of the spine and myelography were performed in all cases. CT-myelography was done in 3 cases. Total block in the myeiogram and bony vertebral changes were the most frequent radiological findings. Tumor location in our series was dorsal (9 cases), lumbar (2 cases) and cervical (1 case). Surgical treatment was given in all cases with apparently total (7 cases) or subtotal (5 cases) tumor removal and dural decompression. Histological examination revealed a non-Hodgkin lymphoma in all cases. Postoperative radiotherapy was performed in all cases and chemotherapy was also administered (C-MOPP) in 6 cases. Median survival was 4 years, with better results in the patients treated with radio-chemotherapy. Improvement of the preoperative defter was observed in 5 patients, the others being unchanged. We discuss the salient clinico-pathological, prognostic and therapeutic features of these tumors in the light of the literature on this topic. Fiorenza F., Salvati M., Artico hi., Scarpinati M., Ramundo Orlando E., Gagliardi EM. (Roma) Cerebral metastases from kidney tumors are not infrequently solitary. 29 intracranial metastasis from kidney neoplasm were studied retrospectively. In 10 cases (34.4%) they represented the first clinical sign of kidney neoplasma which, in one case, only came to light at autopsy. Clinical symptomatology was characterized by signs of intracranial hypertension. For a precise stadiation of the neoplasm the best diagnostic means were CT scan with intravenous contrast medium and MRI with gadolinium. In all patients treatment consisted of surgical removal of the lesion (always macroscopically total) followed by "whole brain" radiation therapy in 20 as well as an oncologic protocol for the primary tumor. The median survival in these cases was 28.1 months in patients who received "whole-brain" radiotherapy and 23 months in the others. In the case where the primary lesion was only found at autopsy, survival was as long as 8 years and death was not due to the neoplastic illness. In 4 patients survival exceeded 4 years. No significant differences emerged between those patients who had cerebral reproduction as the first sign of the illness and those in whom the primary tumor was already known at the time of cerebral diagnosis. In only 5 patients (17.2%) the cause of death was directly related to development of a "brain relapse" and radiotherapy had less influence on further reproduction than in metastases from other tumors.
Solitary brain metastasis from kidney tumors
Solitary brain metastasis from non-oat cell lung cancer
Salvati M., Fiorenza E, Artico M., Capoccia G., Artizzu S., Gagliardi F.M. (Roma) The cerebral parenchima is involved in between 15% and 80% of patients with non-oat cell lung carcinoma: this variability is mainly due to the type of study considered, namely clinical or autoptical. 199 cases of non-oat cell lung carcinoma were retrospectively studied. Patients who died during the operative-perioperative period were excluded. The predominant histotype was adenocarcinoma with 120 cases (60.3%) followed by squamous carcinoma with 67 cases (33.7%). In 91 cases (45.7%) endocranial reproduction was the first clinical sign of a lung neoplasm. In our patients, the best means for intracranial stadiation of the illness was found to be CT with intravenous contrast medium and, particularly, MRI with gadolinium. In 140 of the 199 patients (70.3%) a therapeutic protocol comprising surgical removal of both the intracranial lesion (macroscopically total in 190 out 199 patients ~ 95.5%) and the pulmonary lesion followed, in 120 cases, by integrative treatment (chemotherapy). Whole brain radiotherapy was administered at dosages varying from 30Gy to 55 Gy. Average survival was 25.2 months in patients who followed the entire intracranial protocol and 13 months in those treated by surgery alone. We did not note any statistically significant differences between the survival times of patients who presented with neurological symptoms and those clinical onset was characterized by systemic signs or between different pre-operative Karnofky Performance Status. There was an overall increase in average survival times in those patients in whom the primary tumor remained unknown despite every diagnostic effort made to discover it (29 months). Furthermore, radiation therapy reduced the quota of "Brain relapse" that also appeared to be related to the type of removal performed ("en bloc" or otherwise). Capoccia G., Caruso R., Salvati M., Innocenzi G., Oppido P~4., Gagliardi F.M. (Roma) Cerebral metastases from breast carcinoma are a frequent occurrence during the illness and are solitary in a significant number of cases. The Authors studied 34 cases of solitary cerebral metastasis from operable breast carcinoma. In all cases the female sex was most affected. 18 patients were in menopause. In the majority of cases clinical symptomatology consisted of endocranial hypertension, epileptic seizures or symptoms from deficit. CT with intravenous contrast medium and more recently MRI with gadolinium were the most useful means for an endocranial precise stadiation of the illness. In only 4 cases the mammary lesion was unknown when the endocranial symptoms made their clinical onset and in 1 case it was only discovered at autopsy. All patients underwent surgical removal (macroscopically total in all cases) and 25 received whole-brain radiotherapy. The primay lesion was treated according to the established oncological protocols. In patients treated by surgery plus radiotherapy for the endocraniat lesion, the survival rate at 1 year was 75%, at 2 years 30% with a median survival of 28 months. 6 patients survived for more than 3 years (20%): 4 of these were post-menopausal. Age (pre-menopausal or post-menopausal) did not, however, have a significant influence on survival times in these patients. In patients who did not receive radiotherapy the median survival was 15 months and a greater quota of "brain relapse" occurred. The patient in whom the primary lesion was only found at autopsy survived for 9 years (exitus for diffuse bone and visceral metastases). In 84% of patients the cause of death was due to systemic evolution of the primary tumor.
Solitary cerebral metastasis from breast cancer
Primary malignancies presenting with solitary cerebral metastasis
Salvati M., Ramundo Orlando E., Artico M., Innocenzi G., Gagliardi FM. (Roma) Cerebral metastases account for up 50% of endocranial neoplastic space-occupying lesions and in 33% to 66% of cases represent the initial symptom of a systemic tumor. 188 patients out of a total of 471 who underwent removal of a solitary cerebral metastasis (39.9%) presented neurological disturbances as the first sign of systemic neoplasm. No significant differences in the type of neurological disturbance (intracranial hypertension), sex (male) and decade of life most affected (the sixth) were observed with respect to patients in whom the primary site was known. There was a higher incidence of cerebellar localizations. CT with intravenous contrast medium was sufficient for stadiation of the cerebral lesion in a good number of patients. Search for the primary tumor was carried out using the diagnostic means available at the time , however, in more than 500/0 of cases standard laboratory tests and plain chest x-rays were adeguate for orienting research or individuating the neoplasm. The lung emerged as the most affected organ (site of the initial lesion) fol-lowed by digestive system, the skin (melanoma) and kidney. The mammary gland was particulary unaffected. In 27 patients the tumor was only identified at autopsy, while in another 3, it evaded even this. On the contrary to that reported by other Authors, we did not note any significant differences in survival between these patients and those of the general series (median 14 and 14.3 months respectively). However, in those patients in whom the primary neoplasm was not diagnosed during life, the median survival was significantly better (29.6 months compared to 14). The association of surgery plus radiotherapy (plus, sometimes, chemotherapy) emerged as being better than surgery alone in terms of survival (19.9 months versus 7.3 months) and also seemed to reduce the risk of "brain relapse".
Primitive leptomeningeal melanoma or melanotic malignant schwannoma of the spinal cord? The weight of the electron microscopy.
Bosman C., Boldrini R., Cusimano G., Gagliardi S., lnnocenzi G. (Roma) Melanotic malignant growths origining primarely in the CNS are very rare. Since it is known the common origin from neural crest of melanocytes, meningothelial and Schwann's cells the onset of these neoplasias from meningocytes or Schwann cells has more a semantic than histogenetic value. All three above mentioned cell types may contain melanosomes and are able of malignant growth. The Authors present a case concerning a 43yrs old man complaining of paraplegia and partial incontinence for a previous trauma involving D9 and D10. Since 3 months the patient accused back ache and loss of strenght of the left leg. The NMR revealed a large tumor involving the roots of L4,5 and S1 nerves inside and outside the dural space and bulging ahead of the os sacrum. By means of combined surgery a large black bleeding tumor was removed. The histologic examination denoted a malignant tumor consisting of pleomorphic pigmented atypical cells with abundance of hemorragic and necrotic areas. Immunohistochemical and mostly the ultrastructural study showed the tumor to be leptomenigeal melanoma.
Correlation between AgNORs and other intracranial meningioma parameters.
Oddi G., Visca P., Bruni P., Hernandez R.
(Roma)
Our and other publications take into consideration the peculiarity of intracranial meningioma biological pattern and its correlation with breast cancer. In this study the authors pay attention on some biological parameters of this tumor, as AgNORs, Ki67, C-erb-B2, steroid receptors and histological grading. We observe good positive correlation between Ki67 and AgNORs (dot~ < ! Ix and clusters > 1 Ix, p < 0.001); and for grading. The C-erb-B2 is positive in the more differentiated cellular elements but not overexpressed in these cells differently from breast cancer. The correlation is negative between AgNORs and steroid receptors.
In conclusion, the AgNORs, genetic site of RNA synthesis, have positive correlation with unfavrourable prognostic elements. The Neu oncogene pattern is characteristic in this tumor.
Considerations on one case of craniopharyngioma
Oddi G., Visca P., Br, tni P. Hernandez R. ( Roma) We take into consideration a case of suprasellar rapidly recurrent craniopharyngioma whose biopathological characteristics were investigated in order to check possible aspects related with the clinical behaviour. Classical histology showed the characteristic pattern of such tumors, i.e.: epithelial columnar cells or stratified squamous elements, forming sometimes papillary structures. Sections on paraffin embedded material were prepared for Fuelgen and silver stainings to analyze DNA and Nucleolar Organizer Regions (AgNORs) respectively. The silver stain showed numerous dots in the columnar epithelium and clusters (1-4) in the other population. The DNA index of total population was i.13 (near diploid), but using different scale rates a second small aneupioid peak with DNA index 1.63 was seen in the columnar elements. The AgNORs showed an active cellular synthesis and the DNA an aneuploid population in the columnar elements; both methods recognize a small cellular population, with high proteic amount of nucleolar organizer regions and anomalous chromosomal pattern. Fattaposta F., Cordischi M. V., D'Alessio C., di Venenzio D., Foti A :, Amabile G. (Roma) The Event-Related Potentials or ERPs are a par-512 ticular kind of evoked potentials that can be non invasively recorded from the scalp. They represent the selective cognitive processes that follow a stimulus (Contingent Negative Variation or CNV, P300) or those preparatory ones that precede a movement (Bereitschaftspotentiai or BP). These bioelectricai phenomena show a different topographic distribution on the scalp. So, CNV is more evident in the vertex and bilaterally represented on the centro-parietal areas, with a symmetrical widespread diffusion on the scalp and, finally, BP has a nearly symmetrical distribution with the amplitude over the midline anterior to the Rolandic fissure. Recently, we observed a marked decrease in the amplitude of the earliest component of CNV (Early CNV) on the frontal sites in patients with frontal lesions (e.g. neoplasms). Since CNV is an index of the association processes that one makes between paired stimuli when one is acting as a warning and the other one as an imperative, those CNV modifications can be better seen using a prolonged interstimulus interval. Using a "novelty stimulus" paradigm in the same patients some topographical modifications of the P3 component of the ERPs were observed. To date, there are only few experimental data about anatomical structures generating C NV, P3 and BP. We think that the study of th ERPs in patients with cortical or subcortical cerebral neoplasma, may contribute to a better comprehension of the cortical and/or subcorticai influences on the brain electrical activities that are associated with cognitive processes, and it may be an useful method for monitoring the higher mental functions after therapy. 70. The rhabdoid tumor of the central nervous system; Histopathological, lmmunohistochemicai and Ultrastructural findings. Allegranza A., Cristofori E., Polio B., Rossi G., Verga L., Clemente C. (Milano) The histological, immunohistochemical and uitrastructural findings of four rhabdoid tumors of the CNS are reported. Two tumors were localized in the parietal lobe, one in the frontal lobe and one in the cerebellum. The age of the patients was 3, 7, 31 and 37 years, respectively. One patient was a female and the others males. All the cases showed similar histological features: many tumor cells had abundant cytoplasm with eosinophilic hyaline-like paranuclearinclusion bodies deplacing the nucleus peripherically. The nucleus was large, vescicular, often with cen-tral prominent nucleus. Immunohistochemical staining showed a strong and diffuse vimentin (FIL-3) positivity in three cases and spotty reactivity in one. In a case immunoreactivity for cytocheratin (pool of 35 beta HI 1, 34 beta El2, CAM 5.2, KL1, AEI and AE3) was present. The findings of the uitrastructural study performed on a case revealed the presence of cytoplasmic aggregates of 10 mm intermediate filaments arrangeed in whorled masses corresponding to the inclusions seen by light microscopy and to the vimentin globules seen by immunohistochemistry. Prognosis or rhabdoid tumors is unfavorable. One of our patients displayed recurrence 3 months after surgery and died 3 months later; the second patient was alive and had no signs of recurrence after 16 months; the third patient developed recurrence one month after operation and the last one died six months after the diagnosis. The histogenesis of rhabdoid tumors is still unknown. Many hypotheses about its origin have been suggested: neuroctodermal, mesenchymal, histiocytic and teratomatous. Despite their resemblance to rhabdomiosarcomas, these tumors do not show immunohistochemical and ultrastructural evidence of myogenic origin.
Event-Related Potentials and brain tumors
Expression of H3 histone, vimentin and calcyclin genes in brain tumors
Tonini G.P., Stenger A.M., Garrb M.L., Brisigotti M., Canna A., Di Martino D., Valenti C., Andreussi L., (Genova, BudapesO The cell kinetic analysis can help in the understanding the aggressiveness of the tumor. Tumor cell proliferation can be studied by cytofluorimetry and by in situ measurement of bromodeoxyuridine uptake. However, in the last few years it has been proved that during the different phases of the cell cycle (M, G 1, S and G2) several genes are swiched on or switched off becoming a specific molecular marker of the cell cycle phases. We studied the expression of histone H3 gene (expressed in S phase) and Vimentin gene (expressed in GI phase) in 12 cases of childhood brain tumors. We found that 7/12 samples expressed variously H3 gene; among these, meduiloblastoma, mesenchimal condrosarcoma, gliosarcoma and a carcinoma ofchoroid plexus have very high expression of H3 showing that tumor cells are actively proliferating. Interestingly, the histological analysis of the same tumors revealed high mitotic index. On the contrary, a medulloblastoma and an astrocytoma showing low mitotic index have high expression of H3 gene. This suggests that both histological and molecular analysis could be used to better understand the proliferation state of the tumor cells.
Vimentin gene was found expressed in all samples but at very different levels. Astrocytoma and mesenchimal sarcoma show high expression of the gene with respect to the carcinoma of choroid plexus and medulloblastoma. Two out of three astocytomas showed expression of Vimentin while H3 transcription was not detected; this suggestes that the cells are in GI phase (low proliferation). Calcyclin gene, a G I phase specific gene, is expressed in 8/12 samples; lost of expression was found in medulloblastoma, anaplastic ependymoma, malignant schwannoma and astrocytoma.
Our study demonstrate that S and G l-related genes are differently expressed in the brain tumors. The cells are characterized by remarkable differences in the kinetic of proliferation reflecting a different aggressivity of the tumor. Finally, the analysis of the-cellcycle-dependent gene could also help to design individual therapeutic treatment.
Supported by AIRC.
Neurophysiologieal investigations in patients with extra-or intra-axial tumors in the posterior fossa.
Cruccu G., Coratti P., Innocenti P., Angelini A., Manfredi M., (Roma) Brainstem auditory evoked responses (BAEPs), trigeminal evoked potentials (TEPs), and trigeminal reflexes (blink reflex, masseter silent periods,jawjerk) were studied in 8 patients with cerebello-pontine angle tumors and 8 with intrapontine tumors. The sensivity of the different neurophysiological techniques mainly depended on the site of lesion. BAEPs were abnormal in all patients with acoustic neuroma. Both BAEPs and TEPs were more sensitive in extra-than intra-axial lesions. Of the trigeminal reflexes, the short-latency components (RI, SPI) were more frequently affected in extra-axial lesions and the long-latency components (R2, SP2) in the intra-axial lesions. Although the neurophysioiogical investigations on the whole provide a high sensitivity in posterior fossa tumors, none of the single responses is sufficient.
Transcranial doppler ultrasonography in the intracranial tumoral pathology.
Volpentesta G., Lavano A., Donato G., Habetswallner F., Perino F., Signorelli C.D. ( Catanzaro) auditory nerve compound action potential (AP). Brainstem auditory evoked potentials (BAEPs) are simultaneously obtained in conventional vertex-earlobe derivations. Various patterns of evoked potential alteration are observed following: induction of anesthesia and positioning of the patient; hypothermis; local temperature changes due to irrigation or electroeoagulation; cerebellar retraction and other maneuvers causing traction or pressure on the VIII nerve; severance or occlusion of the Internal auditory artery; fenestration of the semicircular canals; apparently uneventful drilling of the internal auditory canal; and lesions of the intracanallcular portion of the auditory nerve. Certain changes, such as those due to cerebellar retraction, may prove reverable when prompt remedial action is taken. Other irreversible alterations and the attending postoperative deficits have increased the awareness of the potentially hamful effects of certain operative manipulations and prompted modifications of surgical technique almed at preventing them. AEP recording is routinely complemented by monitoring of the motor functions of the V and VII and, whenever appropriate, other cranial nerves. This is achieved by electromyographic (EMG) recordings by fine metal wires inserted in appropriate nudes, generally the temporalls (and/or masseter) for the V nerve; the frontalis, orbicularis oris and mentalis for the VII; the crioothyrold (and/or vocalis) for the X; the trapezius (and/or stemodeidomastoldeus) for the XI; and the geniogiossus muscle for the XII nerve. In the absence of neuromuscular blocking agents, direct electrical stimulation of any of these nerves elicits characteristic compound motor action potentials (CMAPs) which are displayed on an oscilloscope and rendered audible by feeding them through and audio amplifier and speaker. These potentials make it possible to identify and assess the integrity of the nerve throughout the surgical procedure. Failure to obtain them genreally predicits complete loss of motor function post-operatively. We generally monitor SSEPs to median and/or posterior tibial nerve stimulation during removal of spinal cord and cortical tumors. A recent application of neurophysiologic monitoring is the performance of multilevel SSEPs alone or combined with BAEPs during therapeutic embolization of highly vascular tumors and arteriovenous malformations. These recordings are performed during increasingly selective catherizations of cerebral vessels and following tinjections of small amounts of amobarbital sodium and/or reversible occlusion of feeding vessels to help determine the likely functional effects of their permanent obliteration. Loss of evoked potentials during these tests predicts severe postoperative deficits.
